Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
Acerta Pharma Confidential Page 1 PROTOCOL  
TITLE:  An Open -label, Phase 1b Study of ACP -196 in Subjects with  
Relapsed or Refractory de Novo Activated B -cell (ABC) 
Subtype of Diffuse Large B -Cell Lymphoma  
PROTOCOL NUMBER:  ACE-LY-002 
STUDY DRUG:  ACP-196 (acalabrutinib)  
IND NUMBER:  
EUDRACT NUMBER:  118717  
2014 -001341 -25 
SPONSOR MEDICAL 
MONITOR:  Acerta Pharma BV  
Phone:
Email: 
SPONSOR:  Acerta Pharma BV  
5349 AB Oss  
The Netherlands  
Protocol Date:  Version 0.0:   26 March  2014  
Amendment 1 Date:  Version 1.0:  10 June 2014  
Amendment 2 Date:  Version 2.0:  10 March  2015  
Amendment 3 Date: Version 3.0:  13 January 2016  
Amendment 4 Date:  Version 4.0 :  [ADDRESS_473200]/independent ethics committee. This information cannot be used 
for any purpose other than the evaluation or conduct of the clinical investigation without the 
prior written consent of Acerta Pharma BV.  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 2  
PROTOCOL APPROVAL :  AMENDMENT [ADDRESS_473201] carefully read  Protocol  ACE-LY-002 entitled “ An Open -label, Phase 1b Study of 
ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B -cell (ABC) Subtype 
of Diffuse Large B -Cell Lymphoma ”.  I agree to conduct this study as outlined herein and in 
compliance with Good Clinical Practices  (GCP)  and all applicable regulatory requireme nts.  
Furthermore, I understand that the Sponsor , Acerta Pharma , and the Institutional Review 
Board (IRB) /Independent Ethics Committee (IEC)  must approve any changes to the 
protocol in writing before implementation.  
I agree not to divulge to anyone, either  during or after the termination of the study, any 
confidential information acquired regarding the investigational product and processes or 
methods of Acerta Pharma .  All data pertaining to this study will be provided to Acerta 
Pharma .  The policy of Acert a Pharma BV  requires that any presentation or publication of 
study data by [CONTACT_378134] , before release, as 
specified in the protocol.  
 
Principal Investigator’s Signature  [CONTACT_378165]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
Acerta Pharma Confidential Page 3 SUMMARY OF AMENDMENT 4 
This protocol is being amended to add Second Primary Malignancy information, add 
rollover protocol language, and align protocol with the Investigator Brochure. 
Inclusion/Exclusion criteria have not been modified because enrollment closed. 
Clarifying edits and typographical changes have been made throughout the protocol.  In 
addition, the following substantive changes were made as part of this amendment.  
Change  Rationale  
Global Change  
ACP-[ADDRESS_473202] cancer resistance protein  
(BCRP ) substrates.  Updated to align with IB update.  
Section  1.4 Clinical Experience  
Added Calquence® approval lang uage. 
Added reference to Investigator Brochure for 
latest information.  Added  Calquence® approval language.  
Deleted detailed information regarding 
pharmacokinetics, pharmacodynamics, and 
clinical experience.   
Added statement to refer to the Investigator 
Brochure for latest information.  
Section  3.1 Description of Study  
Updated  rollover language.  Updated rollover language for acalabrutinib 
studies.  
Section  3.5.3  Administration of Study 
Drug  
Removed language regarding avoiding 
grapefruit juice and Seville oranges.  Removed tex t to align with IB update.  
Section  3.6.2  Guideline for Use of CYP 
Inhibiting/Inducing Drugs  
Updated  language regarding CYP3A 
inhibitors/inducers.  Updated to align with IB update, CDS, and 
other protocols.  
Section  3.6.[ADDRESS_473203]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 4 Change  Rationale  
Section  3.7.3  Hemorrhage  
Added hemorrhage infor mation.  Added section to align with IB update.  
Section  3.7.4  Infections  
Added information regarding infections.  Added section to align with IB update.  
Section  [IP_ADDRESS]  Progressive Multifocal 
Leukoenc ephalopathy  
Added information regarding progressive 
multifocal leukoencephalopathy  (PML). Added section to align with IB update.  
Section  3.7.[ADDRESS_473204] 
(AESI ). Added AESI  to align  with IB update  
Section  6.2.7  Hy’s Law  
Added se ction with information regarding  
Hy’s law.  Added section to align with IB update.  
Appendix  [ADDRESS_473205]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 5 Change  Rationale  
Appendix  5 Action s Required in Cases of 
Increases in Liver Biochemistry and 
Evaluation of Hy’s Law  
Information regarding Hy’s law added.  Added appendix to align with IB update.  
 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 6 TABLE OF CONTENTS 
PROTOCOL APPROVAL:  AMENDMENT 4 ...........................................................  2 
SUMMARY OF AMENDMENT 4 ................................................................ .............. 3  
TABLE OF CONTENTS ...........................................................................................  6 
ABBREVIATIONS .................................................................................................. 10 
STUDY SYNOPSIS ................................................................................................  13 
1.0 BACKGROUND INFORMA
TION ................................................................  21 
1.1 Diffuse Large B-Cell Lymphoma ................................................................  21 
1.2 Role of Btk in Lymphoid Cancers ..............................................................  23 
1.3 Preclinical Studies ..................................................................................... 24 
1.3.1  Chemistry .......................................................................................  24 
1.3.2  Efficacy Pharmacology ................................................................... 24 
1.3.3  Safety Pharmacology ..................................................................... 25 
1.3.4  Drug-drug Interaction Potential.......................................................  26 
1.3.5  In Vivo General Toxicology ............................................................  26 
1.4 Clinical Experience .................................................................................... 27 
1.5 Benefit/Risk ...............................................................................................  27 
1.6 Summary and Conclusions ........................................................................ 28 
2.0 STUDY OBJECTIVES ................................................................................. 28 
2.1 Primary Objective ......................................................................................  28 
2.2 Secondary Objectives: ............................................................................... [ADDRESS_473206]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473207] Compliance .........................................................  35 
3.5.5  Dose Delays ................................................................................... 35 
3.5.6  Dose Modification and Discontinuation .......................................... 35 
3.6 Concomitant Therapy ................................................................................ 36 
3.6.1  Permitted Concomitant Therapy ..................................................... 36 
3.6.2  Guideline for Use of CYP Inhibiting/Inducing Drugs .......................  [ADDRESS_473208] Gastric pH ..........................  37 
3.6.4  Prohibited Concomitant Therapy .................................................... 37 
3.7 Precautions ................................................................................................  37 
3.7.1  Reference Safety Information .........................................................  37 
3.7.2  Dietary Restrictions ........................................................................ 38 
3.7.3  Hemorrhage ................................................................................... 38 
3.7.4  Infections ........................................................................................  38 
[IP_ADDRESS]  Hepatitis B Virus Reactivation ......................................... 38 
[IP_ADDRESS]  Progressive Multifocal Leukoencephalopathy  .................. 39 
3.7.5  Cytopenias ..................................................................................... 39 
3.7.6  Second Primary Malignancies ........................................................  39 
3.7.7  Atrial Fibrillation .............................................................................. 39 
3.7.8  Surgery ...........................................................................................  40 
3.7.9  Reproductive Toxicity ..................................................................... 40 
3.7.10  Overdose Instructions .................................................................... 41 
3.8 Stoppi[INVESTIGATOR_1869] ..........................................................................................  42 
3.9 Data and Safety Monitoring ....................................................................... 43 
4.0 STUDY ACTIVITIES AND ASSESSMENTS ............................................... 43 
4.1 Description of Procedures ................................
......................................... 44 
4.1.1  Informed Consent ........................................................................... 44 
4.1.2  Medical History ............................................................................... 44 
4.1.3  Adverse Events .............................................................................. 44 
4.1.4  Concomitant Medications and Therapy .......................................... 44 
4.1.5  Confirmation of Eligibility ................................................................  44 
4.1.6  Archival Tumor Sample .................................................................. 44 
4.1.7  ECOG Performance Status ............................................................  44 
4.1.8  Physical Examination, Vital Signs, Height & Weight .......................  [ADDRESS_473209]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 8 4.1.15  T/B/NK Cell Count .......................................................................... 46 
4.1.16  Serum Immunoglobulin .................................................................. 46 
4.1.17  Hepatitis B and C Testing ...............................................................  46 
4.1.18  Pharmacodynamics ........................................................................ 46 
4.1.19  Pharmacokinetics ........................................................................... 47 
4.1.20  Tumor Assessment ........................................................................ 47 
4.1.21  Routine Clinical Assessments ........................................................  48 
4.1.22  Study Drug Accountability ..............................................................  49 
4.2 Investigator’s Assessment of Response to Treatment  ...............................  49 
4.3 Early Termination/Safety Follow-up Visit ................................................... 52 
4.4 Time- to-Next Treatment ............................................................................. 52 
4.5 Missed Evaluations .................................................................................... 52 
5.0 STATISTICAL METHODS OF ANALYSIS .................................................. 53 
5.1 General Considerations ................................
............................................. 53 
5.1.1  Response Assessment ................................................................... 53 
5.1.2  Safety Monitoring ........................................................................... 53 
5.2 Definition of Analysis Sets ......................................................................... 53 
5.3 Missing Data Handling ............................................................................... 53 
5.4 Determination of Sample Size ................................................................... 54 
5.5 Data Analysis .............................................................................................  54 
5.5.1  Safety Parameters .......................................................................... 54 
5.5.2  Demographics and Baseline Characteristics .................................. 54 
5.5.3  Study Treatment Administration and Compliance ..........................  54 
5.5.4  Analysis of Efficacy Parameters ..................................................... 55 
5.5.5  Analysis of Pharmacokinetic/Pharmacodynamic Parameters ........ [ADDRESS_473210]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 9 6.2.6  Type and Duration of Follow-up of Subjects After Adverse 
Events ............................................................................................  62 
6.2.7  Hy’s Law  .........................................................................................  [ADDRESS_473211] Retention .......................................................................................  66 
7.9 Protocol Amend
ments ............................................................................... 66 
7.10  Publication of Study Results ...................................................................... 67 
7.11  Clinical Trial Insurance .............................................................................. 67 
7.12  General Investigator Responsibilities .........................................................  68 
8.0 REFERENCES ............................................................................................  69 
9.0 APPENDICES .............................................................................................  71 
 
In–Text Tables 
 
Table 1-1.  Assessment of ACP- 196 Active-site Occupancy in Fine Needle 
Aspi[INVESTIGATOR_378106] (N=4) ................................ . 25 
Table 3-1.  Drug Discontinuation Actions for Acalabrutinib  ..................................... 36 
Table 4-1.  Pharmacokinetic Sample Schedule ......................................................  47 
Table 4-2.  Response Assessment Criteria for DLBCL (Cheson 2014) .................. 50 
 
Appendices 
 
Appendix 1.  Performance Status Scores ...............................................................  72 
Appendix 2.  Examples of Coadministered Drugs That Need Additional 
Consideration  .................................................................................... 73 
Appendix 3.  Adverse Event Assessment of Causality ........................................... 75 
Appendix 4.  Schedule of Assessments ................................................................ . 76 
Appendix 5.  Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law  ...................................................................... [ADDRESS_473212]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 10 ABBREVIATIONS  
 
Abbreviation  Definition  
ABC activated B -cell (DLBCL subt ype) 
ACP-196 acalabrutinib  
AE(s)  adverse event(s)  
AESIs  adverse events of special interest  
ALT alanine aminotransferase  
ANC  absolute neutrophil count  
anti-HBc hepatitis B core antibody  
ASCO  American Society of Clinical Oncology  
ASCT  autologous stem  cell transplantation  
AST aspartate aminotransferase  
AUC  area under the curve  
BCR  B-cell receptor  
BCRP  breast cancer resistance protein  
BID twice per day (dosing)  
Btk Bruton tyrosine kinase  
BUN  blood urea nitrogen  
CBC  complete blood count  
CFR Code  of Federal Regulations  
cGMP  current Goo d Manufacturing Practices  
CHOP  cyclophosphamide/doxorubicin/vincristine/prednisone  
CL/F  oral clearance  
CLL chronic lymphocytic leukemia  
Cmax maximum observed plasma concentration  
CNS  central nervous system  
CR complete remission (response)  
CSSF  Clinical Supplies Shippi[INVESTIGATOR_378107] P450  
DLBCL  diffuse large B -cell lymphoma  
DLCO  diffuse lung capacity for carbon monox ide 
DOR  duration of response  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 11 Abbreviation  Definition  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EGFR  epi[INVESTIGATOR_378108]  [18F]fluorodeoxyglucose  
GCB  germinal -cell B cell (DLBCL subtype)  
GCP  Good Clinical Practice  
GLP Good Laboratory Practices  
HBsAb  hepatitis B surface antibody  
HBsAg  hepatitis B surface antigen  
HBV hepatitis B virus  
HCV  hepatitis C virus  
hERG  human ether -à-go-go-related gene  
HIV human immunodeficiency virus  
HNSTD  highest nonseverely toxic dose  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IPI [INVESTIGATOR_378109]-term follow up  
MALT  mucosa -associated lymphoid tissue (lymphoma)  
MCL  mantle cell lymphoma  
MedDRA  Medical Dictionary for Regulatory Activities  
NHL non-Hodgkin lymphoma  
NK natural killer (cells)  
ORR  overall response rate  
OS overall survival  
PBMC(s)  peripheral blood mononuclear cells  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 12 Abbreviation  Definition  
PCR  polymerase chain reaction  
PI3K  phosphoinositide -3 kinase  
PMBL  primary mediastinal (thymic) large B -cell lymphoma  
PD pharmacodynamics  
PET positron -emission tomography  
PFS progression -free survival  
PFT pulmonary function test  
PK pharmacokinetics  
PR partial remission (response)  
QD once per day (dosing)  
QM every month  
QTc corrected QT interval  
R-CHOP  rituximab/cyclophosphamide/doxoru bicin/vincristine/prednisone  
R-DHAP  rituximab/cisplatin/cytarabine/dexamethasone  
R-ICE rituximab/ifosamide/etoposide/carboplatin/mesna  
SAE(s)  serious adverse event(s)  
SD stable disease  
SGOT  serum glutamic oxaloacetic transaminase  (also called AST)  
SGPT serum glutamic pyruvic transaminase  (also called ALT)  
SPD sum of the product of the diameters  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction (report)  
t½ terminal elimination half -life (whenever possible)  
λz terminal elimination rate constant (whenever possible)  
Tmax time to maximum drug concentration  
ULN upper limit of normal  
WHO  World Health Organization  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 13  
STUDY SYNOPSIS 
Protocol Number:  ACE-LY-002 
Study Drug:  ACP-196 (acalabrutinib)  
Protocol Title:  An Open -label, Phase 1b Study of ACP -196 in Subjects with 
Relapsed or Refractory de Novo Activated B -cell (ABC) 
Subtype of Diffuse Large B -Cell Lymphoma  
Phase:  Phase 1 b 
Comparator:  None  
Background and 
Rationale for Study  Clinical studies have shown tha t targeting the B -cell receptor 
(BCR) signaling pathway by [CONTACT_378135] 
(Btk) produces significant clinical benefit in patients with 
non-Hodgkin lymphoma (NHL) including diffuse large B -cell 
lymphoma  (DLBCL ).  Ibrutinib, a first genera tion Btk inhibitor, 
has been approved for the treatment of chronic lymphocytic 
leukemia (CLL) and mantle cell lymphoma (MCL) .  Interim 
results from a Phase 2  study of ibrutinib  560 mg once per day 
(QD)  in subjects with relapsed/refractory GCB and ABC 
DLBCL  reported an objective tumor response rate of 41% 
(complete response [CR] 17% and partial response [PR] 24%) 
for subjects with ABC DLBCL versus 5% (no CRs) in subjects 
with germinal -cell B -cell ( GCB ) DLBCL (de Vos  2013 ).  Similar 
results were observed with ONO -4059  (160 to 480  mg QD), a 
second generation Btk inhibitor  in a Phase 1 dose -escalation 
study in subjects with ABC DLBCL .  In both studies, the Btk 
inhibitors were well tolerated.  
Acerta Pharma BV (Acerta  Pharma ) has  developed a novel 
second generation Btk inhibitor, ACP -196 (also known as 
acalabrutinib) , that achieves significant oral bioavailability and 
potency in preclinical models.  Phase 1/[ADDRESS_473213] absorption and rapid clearance that maintains 
optimal target coverage over 24 hours with a dosage of 
100 mg BID.  Acalabrutinib  has been well tolerated in healthy 
volunteers and subjects with CLL or Richter’s syndrome.   
The purpos e of this study is to evaluate the safety, 
pharmacokinetics (PK), pharmacodynamics (PD) , and activity  
of acalabrutinib  administration in  subjects with ABC DLBCL .  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
Acerta Pharma Confidential Page 14 Study Design:  This study i s a multicenter, open-label study .  Twenty 
subjects, 10 refractory and 10 relapsed, will be enrolled and 
will tak e 100 mg of acalabrutinib twice per day (BID).  The 
study will be conducted at approximately [ADDRESS_473214] had a 
PR or better (Cheson 2007 or Cheson 2014 criteria) from the 
previou s anticancer therapy and now have progressed.  
Refractory subjects will be defined as subject s whose bes t 
respon se to the previou s anticancer therapy was stable 
disease or did not respond to therapy.  
Twenty-eight day s of study drug administration i s 1 cycle.  
Treatment wit h acalabrutinib may be continued for >28 days 
until disease progression or an unacceptable drug-related 
toxicity occurs.  Dose modification provision s are provided in 
the study protocol.  Note: temporary withholding of study drug 
for as little as 7 day s can cause a transient worsening of 
disease and/or of constitutional symptoms.  Refer to the 
protocol for more information on assessing disease 
progression under these circumstances.  All subject s who 
discontinue study drug will have a safety follow-up visit 
30 (±7) day s after the last dose of study drug unle ss they have 
started another cancer therapy within that timeframe.  
Radiologi c tumor assessments will be done at 8- to 12-week 
interval s during the trial. [Note: For sites i n [LOCATION_013], 
radiologi c tumor assessments will not include positron 
emission tomography (PET) assessment s and radiologic 
tumor assessments will be done at screening and at the end 
of Cycle [ADDRESS_473215]’s individual 
response; thereafter they will be done at investigator 
discretion].   
All subjects will hav e hematology, chemistry, and urinalysis 
safety panel s done at screening.  Once dosing commences 
(Day 1), all subjects will be evaluated for safety, including 
serum chemistry and hematology, once weekly f or the first 
4 weeks, every 2 week s in Cycle 2 an d monthly thereafter.  
PK/PD testing will be done in Cycle [ADDRESS_473216] etes the 
30-day follow-up visit (if applicable), whichev er occurs first.
Subjects who are still on treatment at the end of the study and 
deriving clinical benefit fr om acalabrutinib treatme nt may 
continue treatment.  At the time of the final data cutoff (DCO) 
and database closure, subj ects who remain in thi s stud y may 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473217] of 
care, whereas the separate rollover study will enable 
treatment continuation with visit assessments and data 
collection per the rollover study protocol.  
Study Objectives:  Primary Obj ective:  
To characterize the safety profile of acalabrutinib in subjects 
with relapsed or refractory ABC DLBCL  
Secondary Objective:  
 To characterize the PK of acalabrutinib  
 To evaluate the PD  effect s of acalabrutinib  
 To evaluate t he activity of acalabrutinib  as measured 
by [CONTACT_30530],  duration of response , time-to-next 
treatment , and progression -free survival  
Efficacy 
Parameters:   Overall response rate  (ORR)  
 Duration of response  
 Progression -free survival  
 Time -to-next treatment  
Safety Parameters:  Type, fre quency, severity, timing of onset, duration, a nd 
relationship to study drug  of any treatment -emergent  adverse 
events (AEs) or abnormalities of laboratory tests; serious 
adverse events (SAEs); or AEs leading to discontinuation or 
dose reduction  of study tre atment.  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 16 Pharmacokinetic 
Parameters:  The plasma  PK of acalabrutinib  will be characterized using 
noncompartmental analysis.  The following PK parameters will 
be calculated, whenever possible, from plasma concentrations 
of acalabrutinib : 
 AUC 0-t:  Area under the plasma concentration -time 
curve calculated using linear trapezoidal summation 
from time [ADDRESS_473218] 
measurable concentration (Ct).  
 AUC 0-12:  Area under the plasma concentration -time 
curve from 0 to 12 hours, calculated using linear 
trapezoidal summation.  
 AUC 0-∞:  Area under the plasma concentration -time 
curve from 0 to infinity, calculated using the formula: 
AUC 0-∞ = AUC 0-t + C t / λz, where λ z is the apparent 
terminal elimination rate constant.  
 AUC 0-24calc:  Area under t he plasma concentration -time 
curve from 0 to 24 hours, calculated by [CONTACT_378136] 0-12. 
 Cmax:  Maximum observed plasma concentration  
 Tmax:  Time of the maximum plasma concentration 
(obtained without interpolation)  
 t½:  Terminal elimination hal f-life (whenever possible)  
 λz:  Terminal elimination rate constant (whenever 
possible)  
 CL/F:  Oral clearance  
Pharmacodynamic 
Parameters:  The occupancy of Btk by [CONTACT_378137] (PBMCs) w ith the aid of a 
biotin -tagged acalabrutini b analogue probe.  The effect of 
acalabrutinib  on biologic markers of B -cell function will also be 
evaluated.  
Sample Size:  Twenty subjects  that consist of  [ADDRESS_473219] relapsed from the previous 
anticancer the rapy.   
Inclusion Criteria:   Men and women ≥ 18 years of age . 
 Eastern Cooperative Oncology Group ( ECOG ) 
performance status of ≤  2. 
 Pathologically confirmed de novo ABC DLBCL, and 
subjects must have available archival tissue for central 
pathology review to be eligible.  
 Relapsed or refr actory disease, defined as either: 
1) recurrence of dise ase after a CR,  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 17 or 2) PR, stable disease (SD), or progressive  disease  at 
completion of the treatment regimen preceding entry to 
the study (residual disease):  
o Subjects must have previously received a s tandard 
anthracycline and rituximab -based first -treatment 
regimen (eg, rituximab/cyclophosphamide/  
doxorubicin/vincristine/prednisone  [R-CHOP ]). 
o Subjects with suspected residual disease after the 
treatment regimen directly preceding study enrollment 
must h ave biopsy demonstration of residual DLBCL.  
o Subjects who have not received high-dose 
chemotherapy/autologous stem cell transplantation 
(HDT/ASCT ) must be ineligible for HDT/ASCT as 
defined by [CONTACT_378138]:  
 Age ≥ 70 years  
 Diffuse l ung capacity for carbon monoxide (DLCO) 
< 50% by [CONTACT_231227] (PFT)  
 Left ventricular ejection fraction ( LVEF) < 50% by 
[CONTACT_18585]  
 Other organ dysfunction or comorbidities 
precluding the use of HDT/ASCT on the basis of 
unacceptable risk of treatment -related morbidity  
 Subject refusal of HDT/ASCT  
o Subjects who are intolerant to  anthracycline -based 
first-line therapy and meet all other eligibility criteria 
including recurrent or refractory disease  are also 
eligible.  
 Presence of radiographically meas urable 
lymphadenopathy or extra nodal lymphoid malignancy 
(defined as the presence of ≥  1 lesion that measures 
≥ 2.[ADDRESS_473220] dimension and ≥ 1.0 cm in the 
longes t perpendicular dimension as assessed by 
[CONTACT_20420] [CT] scan ).  
 Agreement to use acceptable forms of contraception 
during the study and for [ADDRESS_473221] dose of 
study drug  if sexually active and able to bear or beget 
children.   
 Agreement to refrain from sperm donation during the 
study and for [ADDRESS_473222] dose of study  drug.  
 Willing and able to participate in all required evaluations 
and procedures in this study protocol including swallowing 
capsules without difficulty . 
 
 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 18  Ability to understand the purpose and risks of the study 
and provide signed and dated informed cons ent and 
authorization to use protected health information (in 
accordance with national and local patient  privacy 
regulations).  
Exclusion Criteria:   Transformed DLBCL or DLBCL with coexistent 
histologies (eg, follicular lymphoma [ FL] or mucosa -
associated ly mphoid tissue [ MALT ]). 
 Primary mediastinal (thymic) large B -cell lymphoma 
(PMBL) . 
 Known central nervous system (CNS) lymphoma . 
 Prior malignancy, except for adequately treated basal 
cell or squamous cell skin cancer, in situ cervical 
cancer, or other cancer  from which the subjec t has 
been disease free for ≥  2 years or which  will not limit 
survival to <  2 years.  Note: these cases must be 
discussed with the medical monitor . 
 A life -threatening illness, medical condition,  or organ 
system dysfunction which, in t he investigator’s opi[INVESTIGATOR_1649], 
could compromise the subject’s safety, interfere with 
the absorption or metabolism of acalabrutinib , or put 
the study outcomes at undue risk.  
 Significant cardiovascular disease such as 
uncontrolled or symptomatic arrhythmias, con gestive 
heart failure, or myocardial infarction within 6 months 
of screening, or any Class 3 or 4 cardiac disease as 
defined by [CONTACT_115233] , or QTc  > 480 msec . 
 Malabsorption syndrome, disease significantly 
affec ting gastrointestinal function, or resection o f the 
stomach or small bowel , gastric by[CONTACT_6476], symptomatic 
inflammatory bowel disease, or partial or complete 
bowel obstruction.  
 Any immunotherapy within [ADDRESS_473223] dose of 
study drug.  
 The time from the la st dose of the most recent 
chemotherapy or experimental therapy to the first dose 
of study drug is <  5 times the half -life of the previously 
administered agent(s).  
 Radio - or toxin -immunoconjugates within [ADDRESS_473224] dose of study drug . 
 Prior expo sure to a B -cell receptor (BCR) inhibitor 
(eg, Btk, phosphoinositide -3 kinase [PI3K] , or Syk 
inhibitors)  or BCL -2 inhibitors (eg, ABT -199). 
 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 19  Grade ≥ 2 toxicity (other than alopecia ) continuing from 
prior anticancer therapy including radiation . 
 Known histor y of human immunodeficiency virus (HIV), 
serologic status reflecting active hepatitis B or C 
infection, or any uncontrolled active systemic infection.  
Subjects with hepatitis B core antibody positive who 
are surface antigen negative or who are hepatitis C  
antibody positive will need to have a negative 
polymerase chain reaction (PCR) result before 
enrollment.  Those who are hepatitis B surface antigen 
positive or hepatitis B PCR positive and those who are 
hepatitis C PCR positive will be excluded.  
 Major sur gery within [ADDRESS_473225] dose of study 
drug.  
 History of stroke or i ntracranial hemorrhage within 
[ADDRESS_473226] dose of acalabrutinib . 
 History of bleeding diathesis (eg, hemophilia or von 
Willebrand disease)  
 Requires or receiving anticoa gulation with warfarin  or 
equivalent vitamin K antagonists (eg, phenprocoumon) 
within [ADDRESS_473227] dose of study drug . 
 Requires treatment with long -acting proton pump 
inhibitors (eg, omeprazole, esomeprazole, 
lansoprazole, dexlansoprazole, rabeprazole,  or 
pantoprazole)  
 Any of the following laboratory  abnormalities:   
o Absolute  neutrophil count ( ANC ) 
< 750 cells/mm3 (0.75 x 109/L).  For subjects 
with documented bone marrow involvement , 
ANC  < 500 cells/mm3 (0.50 x 109/L) 
o Platelet  count < 50,000 cells/mm3 (50 x 109/L) 
independent of transfusion support .  For 
subjects with documented  bone marrow  
involvement , < 30,000 cells/mm3 (30 x 109/L) 
o Serum  aspartate transaminase  (AST /SGOT ) or 
alanine transaminase  (ALT /SGPT) 
≥ 3.0 x upper limit of normal (ULN)  
o Creatinine > 2.[ADDRESS_473228]   
o Total bilirubin >  2.[ADDRESS_473229] 
 Breast feeding  or pregnant . 
 Concurrent participation in another therapeutic clinical 
trial. 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 20 Dosage Form and 
Strength:  Acalabrutinib  is provided as 100-mg hard gelatin  capsules 
prepared using standard phar maceutical grade excipi[INVESTIGATOR_840].  
Dose 
Regimen/Route of 
Administration:  Acalabrutinib  is an orally administered product.  Acalabrutinib  
may be administered with or without food .  
Regimen:  
100 mg acalabrutinib  (1 x 100 -mg capsules) administered 
12 hours apart (BID d osing = 200-mg total daily dose ) 
Concomitant 
Medications:  Use of proton -pump inhibitors, H2 -receptor antagonists, or 
antacids while taking acalabrutinib is not recommended due to 
a potential decrease in study tr eatment exposure.  If treatment 
with a gastric acid reducing agent is required, use of a 
H2-receptor antagonist (2  hours after acalabrutinib) or antacid 
(2 hours before or 2  hours after acalabrutinib) should be 
considered.  Co -administration of acalabrutin ib with proton 
pump inhibitors should be avoided.   
The concomitant use of acalabrutinib with breast cancer 
resistance protein ( BCRP ) substrates (e.g., prazosin, 
glyburide, nitrofurantoin, dipyridamole, statins, and cimetidine) 
may increase exposure to the  BCRP substrates by [CONTACT_378139], and therefore should be avoided.  
Concomitant use of  strong inhibitors/inducers of CYP3A  
should be avoided when possible.  Subjects requiring 
long-term (>1 week) treatment with a strong CYP3A 
inhibitor/indu cer are excluded from the study.  In addition, the 
use of strong or moderate CYP3A inhibitors or inducers within 
[ADDRESS_473230] 
requires short -term treatment ( ≤7 days) with a strong CYP3A 
inhibitor, acalabrutinib treatment should be interrupted.  If the 
subject requires treatment with a moderate CYP3A inhibitor, 
the acalabrutinib dose should be reduced to [ADDRESS_473231] requires treatment with a strong CYP3A 
inducer, the acalabrutinib dose should be increased to 200  mg 
BID.   
Statistics:  No formal statistical tests of hypotheses will be performed as 
is typi[INVESTIGATOR_21885] a Phase 1b study.  The tri al design is specified 
because of its practical simplicity, use of a biomarker, and not 
because of power considerations.  Descriptive statistics 
(including means, standard deviations, and medians for 
continuous variables and proportions for discrete variab les) 
will be used to summarize data, as appropriate.    
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 21 1.0 BACKGROUND INFORMATI ON 
1.1 DIFFUSE LARGE B-CELL LYMPHOMA 
Diffuse large B-cell lymphoma (DLBCL) is the most common of the aggressive NHL in the 
[LOCATION_002], with an annual incidence that has been rising gradually since the 1990s.  
While approximately half of the incremental rise in incidence of DLBCL is attributable to 
identifiable factors —such as the increase in the incidence of HIV-related DLBCL, the 
evolution of more specific diagnostic techniques, and revisions in lymphoma classification 
schemes —much of the rising incidence remains unexplained.  A very aggressive 
malignancy in its untreated natural history, DLBCL is a potentially curable disease, with a 
significant proportion of patients cured with modern standard chemoimmunotherapy.  
Nonetheless, for those patients not cured by [CONTACT_231235], the prognosis remains 
generally poor, and DLBCL still accounts for the highest number of deaths per year of all 
the NHL histologies. 
Treatment for DLBCL  
Anthracycline-based combination chemotherapy, eg, CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisolone), has been the standard approach to initial 
therapy for DLBCL for decades.  While several variants to the CHOP regimen have been 
developed, often varying by [CONTACT_378140]-intensification of the 
agents, a large multi-arm Phase 3 trial demonstrated no differences in disease-free or 
overall survival (OS) with these “second -generation” variants as c ompared with CHOP 
(Fisher  1993 ).  The addition of rituximab to CHOP (R-CHOP) or CHOP-like regimens, 
however, has resulted in improvement in both disease-free and OS in DLBCL in 3 large 
randomized Phase 3 trials ( Coiffier  2002, Habermann  2006, Pfreundschuh  2006).  
Long-term follow-up of the GELA LNH-98.5 study confirmed that a greater proportion of 
patients are cured using R-CHOP compared with CHOP alone ( Coiffier  2010 ). 
For patients with either residual or recurrent DLBCL following initial therapy, the approach 
of re-induction chemotherapy, followed by [CONTACT_5019]-dose chemotherapy with autologous stem 
cell support (HDT/ASCT) for responding patients, remains the current standard of care.  
Such an approach was demonstrated to result in superior disease-free survival compared 
with re-induction chemotherapy-alone in a randomized Phase 3 trial ( Philip  1995).  
However, the results of a more recently reported Phase 3 trial comparing rituximab, 
ifosfamide, carboplatin, and etoposide (R-ICE) to rituximab, cisplatin, cytarabine, and 
dexamethasone (R- DHAP ) as re-induction therapy suggests that this standard salvage 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473232]-line therapy (Gisselbrecht  et al 2010 ).  In addition, HDT/ASCT is 
associated with considerable treatment-related morbidity and occasional treatment-related 
mortality.  Advanced age and suboptimal baseline pulmonary or cardiac function are risks 
for excessive morbidity during and after HDT/ASCT.  Therefore, effective and tolerable 
therapi[INVESTIGATOR_378110], particularly in the era of 
rituximab-based initial chemoimmunotherapy.  
Clinical and Molecular Markers of Prognosis 
The major clinical prognostic factors for NHL are well described and have been 
incorporated into the International Prognostic Index (IPI) scoring system.  The specific 
factors are: age > 60 years, stage III or IV disease, performance status ≥ 2, and elevated 
lactate dehydrogenase (LDH) levels.  These factors are combined in the IPI [CONTACT_182276] 
4 categories, with 5-year progression-free survival (PFS) ranging from 40% to 70% and 
5-year OS ranging from 26% to 73% among patients treated with CHOP 
(International Non- Hodgkin’s  Lymphoma Prognostic Factors Project , 1993 ).  Regarding 
applicability of the IPI [INVESTIGATOR_378111] (eg, R-CHOP), a recent 
report of a large series of patients treated with rituximab-based regimens found the IPI 
[INVESTIGATOR_378112]-free and overall survival ( Ziepert  2010).  
DLBCL is a heterogeneous disease not only clinically, but also morphologically and 
molecularly.  Recent progress has been made in terms of understanding and categorizing 
the molecular heterogeneity of DLBCL.  In a retrospective analysis of a large series of 
patients with DLBCL, The Leukemia and Lymphoma Molecular Profiling Project used DNA 
microarray to identify distinct gene-expression profiles on the basis of hierarchical 
clustering ( Rosenwald  2002) .  Two principal independent gene-expression subgroups were 
identified: germinal-center B cell (GCB) and activated B cell (ABC).  When outcome after 
standard chemotherapy was analyzed, the GCB and ABC subgroups were not only 
prognostically distinct in direct comparison (with superior outcome in the GCB subgroup), 
but this prognostic distinction was also independent of the IPI.  Therefore, it may be 
possible to distinguish prognostic subgroups of DLBCL on a molecular as well as clinical 
basis. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 23 1.2 ROLE OF BTK IN LYMPHOID CANCERS 
Bruton tyrosine kinase (Btk) is a non-receptor enzyme of the Tec kinase family that is 
expressed among cells of hematopoietic origin, including B cells, myeloid cells, mast cells 
and platelets, where it regulates multiple cellular processes including proliferation, 
differentiation, apoptosis, and cell migration (Mohamed  2009, Bradshaw  2010 ).  Functional 
null mutations of Btk in humans cause the inherited disease, X-linked 
agammaglobulinemia, which is characterized by a lack of mature peripheral B cells 
(Vihinen  2000) .  Conversely, Btk activation is implicated in the pathogenesis of several 
B-cell malignancies ( Buggy  2012) .  Taken together, these findings have suggested that 
inhibition of Btk may offer an attractive strategy for treating B-cell neoplasms. 
Ibrutinib (IMBRUVICA ™), a first generation oral, small-molecule Btk inhibitor has been 
approved for the treatment for CLL and MCL .  Interim results from a Phase 2 study of 
ibrutinib 560 mg QD in subjects with relapsed/refractory GCB and ABC DLBCL reported an 
objective tumor response rate of 41% (CR 17% and PR 24%) for subjects with ABC DLBCL 
(N=29) versus 5% (no CRs) in subjects with GCB DLBCL (N=20) ( de Vos  2013).   In a 
Phase 1 dose-escalation study (160 to 480 mg QD) of ONO-4059, a second generation Btk 
inhibitor, in subjects with ABC DLBCL an ORR of 47% (7/15) was observed ( Dyer  2014 ).  
Also subjects who were refractory to the prior anticancer therapy had an ORR of 33% (3/9) 
compared with an ORR of 67% (4/6) for subjects who had relapsed after the prior therapy.  
In both studies, the Btk inhibitors were well tolerated. 
While highly potent in inhibiting Btk, ibrutinib has also shown in vitro activity against other 
kinases with a cysteine in the same position as Cys481 in Btk to which the drug covalently 
binds.  The inhibition of epi[INVESTIGATOR_3506] (EGFR) is also observed in 
cellular assays and may be the cause of ibrutinib-related adverse events (AEs) of diarrhea 
and rash (IMBRUVICA® package insert).  In addition, ibrutinib is a substrate for CYP3A4; 
inhibition of CYP3A causes a 29-fold increase in maximum concentration (C max) and 24-fold 
increase in area under the curve (AUC) for ibrutinib (IMBRUVICA® package insert).  This 
increases the possibility of drug-drug interactions in combination therapi[INVESTIGATOR_378113].  These liabilities support the 
development of alternative Btk inhibitors for use in the therapy of B-cell malignancies. 
Chemical optimization, pharmacologic characterization, and toxicologic evaluation have led 
to identification of ACP-196 (also known as acalabrutinib),  an orally bioavailable, new 
chemical entity that covalently inhibits Btk and shows encouraging activity and acceptable 
safety in nonclinical studies.  Within the class of Btk inhibitors, acalabrutinib  is a more 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 24 selective inhibitor of Btk than ibrutinib.  Key nonclinical differentiators of acalabrutinib  
versus ibrutinib are: 
 Acalabrutinib  has been evaluated against ibrutinib in EGFR expressing cell lines.  
Ibrutinib is a potent covalent inhibitor of EGFR (EC50 = 50 to 70 nM).  Acalabrutinib 
does not inhibit EGFR even at the highest concentration tested (10 μM).  
 Acalabrutinib  has been evaluated against ibrutinib in in vitro antibody- dependent 
cell-mediated cyto toxicity (ADCC) assays.  At physiologic concentrations, ibrutinib, 
but not acalabrutinib , reduced natural killer (NK) cell-mediated lysis of Raji and 
autologous CLL tumor cells and significantly inhibited rituximab-induced NK cell 
cytokine secretion (P<0.05).  
 Acalabrutinib  has been evaluated against ibrutinib in an in vivo thrombus formation 
model.  At physiologic concentrations, ibrutinib, but not acalabrutinib , significantly 
inhibited thrombus formation (P=0.001).  
The nonclinical and toxicology results of acalabrutinib  suggest it may have an improved 
therapeutic window relative to ibrutinib; it may be more readily combined with other agents 
for the treatment of cancer.   
1.3 PRECLINICAL STUDIES 
Summaries of preclinical studies are provided below.  For more detailed information please 
refer to the Investigator Brochure.  
1.3.1 Chemistry 
Acalabrutinib  is an imidazopyrazine analogue with a molecular weight of 465.5 g/mol.  The 
compound has 1 stereogenic center and acalabrutinib  is the S-enantiomer.  Acalabrutinib is 
orally bioavailable in humans and is suitable for formulating in capsules.  For clinical 
testing, acalabrutinib  has been manufactured and formulated according to current Goo d 
Manufacturing Practices (cGMP). 
1.3.2 Efficacy Pharmacology 
Spontaneous canine B-cell lymphoma shares many characteristics with human NHL, 
including diagnostic classifications and response to Btk inhibition (Honigberg  2010 ).  The 
life expectancy in untreated animals with aggressive disease is ~6 weeks, thus enabling 
rapid assessment of drug efficacy ( Vail 2004).  ACP-[ADDRESS_473233]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473234] ranged from 2.5 to 20 mg/kg QD or BID.  To date, per 
Veterinary Cooperative Oncology Group criteria for assessment of response in peripheral 
nodal lymphoma (Vail 2010 ), PRs been observed in 4 of 14 dogs (29%) and stable disease 
(SD) has been observed in 8 of 14 dogs (57%) ( Gardner  2014).  No ACP-[ADDRESS_473235] been reported to date in this study.  These findings are preliminary and similar to the 
clinical responses (ie, 1 dog with PR out of 5 dogs treated with suspected or confirmed 
DLBCL) observed with ibrutinib in dogs with spontaneous B-cell lymphoma 
(Honigberg 2010 ). 
Preliminary results assessing Btk occupancy using a biotin-tagged analogue of ACP-196 
show near complete Btk occupancy over 24 hours with BID versus QD dosing in canine 
tumor tissue ( Table 1-1 ).   
Table 1-1.  Assessment of ACP- 196 Active-site O ccupancy in Fine Needle Aspi[INVESTIGATOR_378114] (N=4) 
Timing  Dog Identification and ACP -196 Dosing Regimen  
DL-10 DL-12 DL-14 DL-16 
5 mg/kg QD 10 mg/kg BID 20 mg/kg QD  20 mg/kg QD  
Btk Occupancy (% versus predose)  
Day 1 (3 hours after 
morning dose)  98% 99% 98% 99% 
Day 7 (before 
morning dose)  80% 98% 77% 93% 
BID = twice per day; Btk = Bruton tyrosine kinase; ND = not determined; QD = once per 
day 
1.3.[ADDRESS_473236] the A3 adenosine 
receptor; follow-up dose-response experiments indicated a IC 50 of 2.7 µM, suggesting a low 
clinical risk of off-target effects.  ACP-196 at 10 μM showed no inhibition of in vitro 
epi[INVESTIGATOR_3506] (EGFR) phosphorylation in an A431 human epi[INVESTIGATOR_378115], whereas ibrutinib had an IC [ADDRESS_473237] of ACP-196 on human ether-à- go-go-related gene (hERG) channel 
activity was investigated in vitro in human embryonic kidney cells stably transfected with 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 26 hERG.  ACP-196 inhibited hERG chan nel activity by 25% at [ADDRESS_473238] in vivo Good Laboratory Practices (GLP) studies of 
pharmacologic safety.  A functional observation battery in rats at doses of through 
300 mg/kg (the highest dose level) revealed no adverse effects on neurobehavioral effects 
or body temperature at any dose level.  A study of respi[INVESTIGATOR_378116] -related adverse effects at doses through 300  mg/kg (the highest dose level).  
In a cardiovascular function study in awake telemeterized male b eagle dogs, single doses 
of ACP-196 at dose levels through 30  mg/kg (the highest dose level) induced no 
meaningful  changes in body temperature, cardiovascular, or electrocardiographic (ECG) 
(including QT interval) parameters.   The results suggest that ACP-[ADDRESS_473239] CYP -mediated metabolism of ACP-196 appears to be 
catalyzed predominantly by [CONTACT_097]3A4/5.  However, in elimination studies in preclinical 
species, the metabolic fate of ACP-[ADDRESS_473240] conjugation of ACP-196 with 
glutathione, providing evidence for a significant non-CYP mechanism of elimination.  In a 
healthy volunteer study (ACE -HV-001), the effect of coadministration of a potent CYP3A 
and P -gP inhibitor, itraconazole, on the plasma levels of ACP-[ADDRESS_473241] that ACP-196 is not anticipated to alter the 
PK of other therapeutic agents that are substrates for MDR1 , OATP1B1, OATP1B3, OAT1, 
OAT3 and OCT2.  ACP -196 (200  mg QD) may alter the PK of breast cancer resistance 
protein ( BCRP ) substrates by [CONTACT_378141] .  Caution should be taken when 
coadminister ed with narrow therapeutic index BCRP substrate s.  
1.3.5  In Vivo General Toxicology  
To date, the toxicology program has include d 28-day GLP evaluations in  rats and dogs.  In 
the 28 -day study in male and female Sprague -Dawley rats, animals re ceived oral gavage 
ACP-196 dosages  of 30, 100, and 300  mg/kg/day.  In the [ADDRESS_473242]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 27 beagle dogs, animals received oral  ACP-196 dosages  of 3, 10, and 30  mg/kg/day.  Both 
studies had [ADDRESS_473243] level in the dog was 30  mg/kg/day, which was the 
highest dose e valuated.  In rats, 30  mg/kg/day resulted in minimal inflammation of the 
pancreas in some animals , with reversal, indicating the rat to be the more sensitive 
preclinical species.  The pancreatic effects were minimally increased at 100  mg/kg/day in 
the rat though there was no clinical evidence of toxicity.  Hence,  100 mg/kg/day was 
selected to conservatively represent the highest nonseverely toxic dose ( HNSTD ).  The 
pancreatic findings were investigated in subsequent rat toxicology studies and found to be 
treatment related, non-adverse at lower doses, and not associated with systemic toxicity or 
changes in biomarkers of pancreatic function.  The islet cell changes resemble a 
spontaneous pancreatic lesion that is described as an age -related finding in male rat s of 
this strain.  In dogs at 30  mg/kg/day, no adverse effects on the pancreas were observed ; 
there were no microscopic findings in the pancreas, and all clinical biomarkers of 
pancreatic function were normal.  
In rats and dogs, no adverse ECG or histopath ologic cardiovascular effects were noted at 
the planned conclusion of the 28 -day toxicology studies.  However, in 5 of 6 rats from the 
300-mg/kg group that died early in the study, slight to moderat e necrosis of the 
myocardium  and/or white blood cell infil tration/inflammation of the myocardium were noted 
on microscopic examination of the hearts.  These findings were most likely incidental 
postmortem changes.  
1.4 CLINICAL E XPERIENCE  
Calquence® has been approved in the [LOCATION_002] and other markets for the tre atment of 
adult patients with MCL who have received at least one prior therapy, CLL, and small 
lymphocytic lymphoma (SLL).     
For the latest information for pharmacokinetics  and pharmacodynamics  and clinical 
experience, see the Investigator Brochure.  
1.5 BENEF IT/RISK  
Acalabrutinib  is a potent, orally available small -molecule inhibitor of Btk.  A PK/PD study 
has been completed with acalabrutinib  in healthy volunteers (ACE -HV-001; see Investigator 
Brochure ).  The safety results showed no identified safety risks i n healthy subjects 
receiving 1 or 2 days of acalabrutinib  ≤ 100 mg.  In study ACE -CL-001, a study of 
acalabrutinib  in subjects with relapsed/refractory or previously untreated CLL or Richter’s 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473244] been reported at dosages of ≤  400 mg QD or 100 and 200 mg 
BID.  The overall response rate in the evaluable subjects for this study is currently 94% with 
some subjects obtaining PRs after only [ADDRESS_473245] of this study is supported by [CONTACT_378142][INVESTIGATOR_378117]; knowledge of the efficacy 
and safety of other Btk inhibitors (eg, ibrutinib and ONO- 4059 )  in subjects with hematologic 
cancers; and the available nonclinical and clinical information regarding acalabrutinib .  
2.0 STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
To characterize the safety profile of acalabrutinib  in subjects with relapsed or refractory 
ABC DLBCL 
2.2 SECONDARY OBJECTIVES: 
 To characterize the PK of acalabrutinib   
 To evaluate the PD effects of acalabrutinib  
 To evaluate the activity of acalabrutinib  as measured by [CONTACT_30530], duration o f 
response, time- to-next treatment, and progressi on-free survival 
3.[ADDRESS_473246] had a PR or better (Cheson  2014  
or Cheson  2007 criteria) from the previous anticancer therapy and now have progressed.  
Refractory subjects will be defined as subjects whose best response to the previous 
anticancer therapy was SD or did not respond to therapy.  
Treatment with acalabrutinib may be continued for > [ADDRESS_473247]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 29 Section 3.5.5 .  Note: temporary withholding of study drug for as little as 7 days can cause a 
transient worsening of disease and/or of constitutional symptoms.  Refer to Section 3.[ADDRESS_473248] a safety follow-up visit 30 (±7) days after the 
last dose of study drug unless they have started another cancer therapy within that 
timeframe.  
All subjects will have hematology, chemistry, and urinalysis safety panels done at 
screening.  Once dosing commences (Day 1), all subjects will be evaluated for safety, 
including serum chemistry and hematology, once weekly for the first 4 weeks, every 
2 weeks in Cycle 2 and monthly thereafter.  PK/PD testing will be done in Cycle [ADDRESS_473249] 
enrolled completes the end of Cycle 12 or withdraws for any reason and completes the 
30-day follow-up visit (if applicable), whichever occurs first. 
Subjects who are still on treatment at the end of the study and deriving clinical benefit from 
acalabrutinib treatment may continue treatment.  At the time of the final data cutoff (DCO) 
and database closure, subjects who remain in this study may be transitioned to a separate 
rollover study or remain within this study for continued access to study drug.  Once all 
active subjects are eligible to continue to receive acalabrutinib and after database closure, 
this study would be considered closed.  There will be no further data collection other than 
reporting of SAEs per Section 6.2.[ADDRESS_473250] been established for lymphoma 
(Cheson  2014 ); assessments of acalabrutinib  efficacy in this study will be based on these 
Lugano criteria.  Efficacy endpoints will include: 
 ORR 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 30  Duration of response 
 Progression-free survival 
 Time- to-next treatment 
3.2.2 Safety Parameters 
The safety of acalabrutinib  will be characterized by [CONTACT_89852], frequency, severity, timing of 
onset, duration, and relationship to study drug of any treatment-emergent AEs  or 
abnormalities of laboratory tests; SAEs; or AEs leading to discontinuation or dose reduction 
of study treatment.  
For consistency of interpretation, AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), and the severity of AEs and laboratory abnormalities will 
be graded using the Common Terminology Criteria for Adverse Events (CTCAE) , 
Version 4.03.  Standard definitions for seriousness will be applied (see Section 6.1). 
3.2.[ADDRESS_473251] PK parameters for acalabrutinib in plasma will be evaluated in this study.  A full 
description of the PK parameters is provided in Section 5.5.5 . 
The occupancy of Btk by [CONTACT_378143] (PBMCs) with the aid of a biotin-tagged acalabrutinib  analogue probe.  The effect of 
acalabrutinib  on biologic markers of B-cell function will also be evaluated. 
PK/PD assessments will only be done in subjects at sites in the [LOCATION_002] only. 
3.3 RATIONALE FOR STUDY DESIGN AND DOSING REGIMEN 
Preliminary data from the ongoing Phase 1/[ADDRESS_473252] shown that 
acalabrutinib  is well tolerate at dosages of 100 to 400 mg QD and 100 to 200 mg BID.  In 
addition, preliminary PD data from ACE-CL-001 show that Btk occupancy > 95% in 
peripheral blood is observed 4 hours after dosing but decreases to < 95% occupancy at 
24 hours, while with BID dosing complete Btk occupancy (95% to 99%) is maintained over 
[ADDRESS_473253] that de novo synthesis of Btk can occur 
within 24 hours in peripheral blood cells.  BID dosing may ensure Btk inhibition for the 
entire 24 hours and thus may be beneficial in terms of increased efficacy and/or decreased 
development of resistance to acalabrutinib .  In addition, having information regarding the 
safety and pharmacology of a BID schedule may support future combination studies with 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 31 other drugs that are given BID.  Therefore, this study has been designed to evaluate the 
safety, PK, PD, and activity of dosing with 100  mg BID dosing in s ubjects with ABC DLBCL.  
3.4 SELECTION OF STUDY P OPULATION  
3.4.1  Inclusion Criteria  
Eligible subjects will be considered for inclusion in this study if they meet all of the following 
criteria:  
1. Men and  women ≥ 18 years of age.  
2. Eastern Cooperative Oncology Group ( ECOG ) performance status of ≤  2. 
3. Pathologically confirmed de novo ABC DLBCL, and subjects must have available 
archival tissue for central pathology review to be eligible.  
4. Relapsed or refractory disease, defined as either: 1) recurrence of disease after a 
CR, or 2) PR, SD, or progressive  disease at completion of the treatment regimen 
preceding entry to the study (residual disease):  
o Subjects must have previously received a standard anthracycline an d 
rituximab -based first -treatment regimen (eg, R-CHOP ). 
o Subjects with suspected residual disease after the treatment regimen 
directly preceding study enrollment must have biopsy demonstration of 
residual DLBCL.  
o Subjects who have not receiv ed HDT/ASCT  must  be ineligible for 
HDT/ASCT as defined by [CONTACT_378138]:  
 Age ≥  70 years  
 Diffuse lung capacity for carbon monoxide (DLCO) < 50% by [CONTACT_378144]  
 Left ventricular ejection fraction (LVEF) < 50% by [CONTACT_18585]  
 Other organ dysfunction or comorbidities p recluding the use of 
HDT/ASCT on the basis of unacceptable risk of treatment -related 
morbidity  
 Subject refusal of HDT/ASCT  
o Subjects who are intolerant to  anthracycline -based first -line therapy and 
meet all other eligibility criteria including recurrent or refractory disease  are 
also eligible.  
5. Presence of radiographically meas urable lymphadenopathy or extra nodal lymphoid 
malignancy (defined as the presence of ≥  1 lesion that measures ≥ 2.[ADDRESS_473254] dimension and ≥ 1.[ADDRESS_473255]  scan ).  
6. Agreement to use acceptable forms of contraception during the stu dy and for 
[ADDRESS_473256]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473257] dose of study drug.  
8. Willing and able to participate in all  required evaluations and procedures in this 
study protocol including swallowing capsules without difficulty . 
9. Ability to understand the purpose and risks of the study and provide signed and 
dated informed consent and authorization to use protected health i nformation (in 
accordance with national and local patient  privacy regulations).  
3.4.2  Exclusion Criteria  
Subjects will be ineligible for this study if they meet any of the following criteria:  
1. Transformed DLBCL or DLBCL with coexistent histol ogies (eg, FL or MALT ) 
2. Primary mediastinal (thymic) large B -cell lymphoma (PMBL)  
3. Known central nervous system (CNS) lymphoma  
4. Prior malignancy, except for adequately treated basal cell or squamous cell skin 
cancer, in situ cervical cancer, or other cancer from which the subject  has been 
disease free for ≥  2 years or which will not limit survival to < 2 years.  Note: these 
cases must be discussed with the medical monitor . 
5. A life -threatening illness, medical condition , or organ system dysfunction which, in 
the investigator’s opi[INVESTIGATOR_21677], could compromise the subject’s safety, interfere with the 
absorption or metabolism of acalabrutinib , or put the study outcomes at undue risk.  
6. Significant cardiovascular disease such as uncontrolled or symptomatic 
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of 
screening, or any Class 3 or 4 cardiac disease as defined by [CONTACT_378145] , or QTc  > [ADDRESS_473258] dose of study drug is <  5 times the half -life of the previously 
administered agent(s).  
10. Radio - or toxin -immunoconjugates within [ADDRESS_473259] dose of study drug  
11. Prior exposure to a B-cell recepto r (BCR ) inhibitor (eg, Btk phosphoinositide -3 
kinase [PI3K] , or Syk  inhibitors)  or BCL -2 inhibitors (eg, ABT -199). 
12. Grade ≥ 2 toxicity (other than alopecia ) continuing from prior anticancer therapy 
including radiation . 
13. Known history of human immunodeficienc y virus (HIV), serologic status reflecting 
active hepatitis B or C infection, or any uncontrolled active systemic infection.  
Subjects with hepatitis B core antibody positive who are surface antigen negative or 
who are hepatitis C antibody positive will ne ed to have a negative PCR  result before 
enrollment.  Those who are hepatitis B surface antigen positive or hepatitis B PCR 
positive and those who are hepatitis C PCR positive will be excluded.  
14. Major surgery within [ADDRESS_473260]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473261] dose of 
acalabrutinib . 
16. History of bleeding diathesis (eg, hemophilia or von Willebrand disease) 
17. Requires or receiving anticoagulation with warfarin or equivalent vitamin K 
antagonists (eg, phenprocoumon) within [ADDRESS_473262] dose of study drug. 
18. Requires treatment with long-acting proton pump inhibitors (eg, omeprazole, 
esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) 
19. Any of the following laboratory abnormalities:  
a. Absolute neutrophil count ( ANC ) < 750 cells/mm3 (0.75 x 109/L).  For 
subjects with documented bone marrow involvement , ANC  < 500 cells/mm3 
(0.50 x 109/L) 
b. Platelet count < 50,000 cells/mm3 (50 x 109/L) independent of transfusion 
support.  For subjects with documented bone marrow involvement , < 30,000 
cells/mm3 (30 x 109/L) 
c. Serum AST/SGOT or ALT/SGPT ≥ 3.[ADDRESS_473263]  
d. Creatinine > 2. [ADDRESS_473264]  
e. Total bilirubin > 2.[ADDRESS_473265] into the study will be performed according to the following 
procedure:  
 The study center will notify the sponsor when a clinically eligible subject is identified and 
is ready to screen, to ensure enrollment availability on the study. 
 After the subject has signed and dated the Informed Consent Form (ICF), all screening 
procedures have been completed, and eligibility has been confirmed, the subject can be 
officially enrolled in the study.  
 To enroll a subject, the study center will fax/email a completed Enrollment Confirmation 
Form to the sponsor.  The enrollment date will be the date that the form is 
faxed/emailed to the sponsor. 
 An Enrollment Confirmation Form will be completed and faxed/emailed to the study 
center by [CONTACT_86622] [ADDRESS_473266] begin within the screening window ( Section 4.1) and after the site has 
received notification from the sponsor.  Study treatment is not blinded on this study. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473267].   
Acalabrutinib  capsules contain 100 mg drug substance .  Acalabrutinib will be provided in 
white, high-density polyethylene bottles. 
If a drug shipment arrives damaged, or if there are any other drug complaints, a 
SAE/Product Complaint Form should be completed and emailed or faxed to the sponsor or 
the sponsor’s represen tative.   
Refer to the Investigator Brochure for additional information. 
3.5.[ADDRESS_473268] ensure that subjects receive 
acalabrutinib  only from personnel who fully understand the procedures for administering the 
drug. 
Acalabrutinib  is intended to be administered orally with 8 ounces (approximately 240 mL) of 
water.  Subjects may take study drug with or without f ood.  The capsules should be 
swallowed intact and subjects should not attempt to open capsules or dissolve them in 
water .  Dietary restrictions are provided in Section 3.7.[ADDRESS_473269].   
If a dose is missed, it can be taken within 3 hours after the scheduled time with a return to 
the normal schedule with the following dose.   If the time from the scheduled time of 
administration has been > [ADDRESS_473270]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473271] number of capsules needed for use until the next visit. 
3.5.5 Dose Delays 
Treatment with acalabrutinib  should be held for any unmanageable, potentially study 
drug-related toxicity that is Grade ≥ [ADDRESS_473272] be discussed 
with the medical monitor.  Study drug may be held for a maximum of 28 consecutive days 
from expected dose due to toxicity.  Study treatment should be discontinued in the event of 
a toxicity lasting > 28 days, unless reviewed and approved by [CONTACT_7195]. 
Note: temporary withholding of study drug for as little as 7 days can cause a 
transient worsening of disease and/or of constitutional symptoms.   Refer to 
Section 3.8 for more information on assessing disease progression under these 
circumstances. 
3.5.6 Dose Modification and Discontinuation 
The actions i n Table 3-1  should be taken for the following toxicities: 
 Grade 4 ANC (< 500/μL) for > 7 days (Neutrophil growth factors are permitted per 
ASCO guidelines [ Smith  2006 ] and use must be recorded on the electronic case 
report form [eCRF]). 
 Grade 3 platelets in presence of significant bleeding 
 Grade [ADDRESS_473273]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 36  Grade 3 or 4 nausea, vomiting, or diarrhea, if persistent despi[INVESTIGATOR_378118] c 
and/or anti-diarrheal therapy 
 Any other Grade [ADDRESS_473274] - 2nd Hold acalabrutinib  until recovery to Grade ≤ 1 or baseline; may restart at 
original dose level   
3rd Hold acalabrutinib  until recovery to Grade ≤ 1 or baseline; rest art at [ADDRESS_473275]/caregiver about the change in dose level.  Any changes to the dosing regimen 
must be recorded in the Dosage Administration eCRF.   
3.[ADDRESS_473276] supportive care medications are 
permitted as per institutional standards.   
For subjects considered at risk for tumor lysis syndrome:   Administer appropriate hydration , 
alkalinization of urine, and allopurinol or rasburicase per institutional standards before 
initiating treatment. 
3.6.2 Guideline for Use of CYP Inhibiting/Inducing Drugs 
At the systemic exposure levels expected in this study, acalabrutinib inhibition of CYP 
metabolism is not anticipated.  However, concomitant administration of acalabrutinib  with a 
strong CYP3A4 inhibitor increased exposure by [CONTACT_3450] 5-fold ( see Investigator 
Brochure ).  Consequently, the concomitant use of strong inhibitors/inducers of CYP3A4 
(Appendix 2 ) should be avoided when possible.  Subjects requiring long-term (>1 week) 
treatment with a strong CYP3A inhibitor/inducer are excluded from the study.  In addition, 
the use of strong or moderate CYP3A inhibitors or inducers within [ADDRESS_473277] requires short- term treatment (≤7 days) with a strong 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473278] 
(2 hours after acalabrutinib) or  antacid (2  hours before or 2  hours after acalabrutinib) 
should be considered.  Co -administration of acalabrutinib with proton pump inhibitors 
should be avoided.   
The concomitant use of acalabrutinib with BCRP substrates (e.g., prazosin, glyburide, 
nitrof urantoin, dipyridamole, statins, and cimetidine) may increase exposure to the BCRP 
substrates by [CONTACT_378141], and therefore should be avoided.  
3.6.4  Prohibited Concomitant Therapy  
Any chemotherapy , immunotherapy , corticosteroids ( > 10 mg of pre dnisone or equivalent ), 
kinase inhibitors , bone marrow transplant ation , experimental therapy, warfarin, and 
radiotherapy are prohibited.    
3.7 PRECAUTIONS  
3.7.1  Reference Safety Information  
For the purpose of reporting AEs and serious adverse events (SAEs):  
The Inve stigator Brochure contains the Reference Safety Information (RSI) for 
acalabrutinib.  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473279] using herbal remedies or dietary 
supplements (in particular, St John’s wort, which is a potent CYP3A inducer).  Otherwise, 
subjects should maintain a normal diet unless modifications are required to manage an AE 
such as diarrhea, nausea, or vomiting.  
3.7.[ADDRESS_473280]-surgery.  Subjects with hemorrhage should be managed per institutional 
guidelines with supportive care and diagnostic evaluations as clinically indicated.  
3.7.4 Infections    
Serious infections (bacterial, viral, and fungal), including fatal events, have occurred in 
clinical studies with acalabrutinib.  The most frequent reported Grade ≥3 infection was 
pneumonia (preferred term).  
Consider prophylaxis in subjects who are at increased risk for opportunistic infections.  
Subjects should be monitored for signs and symptoms of infection and treated as medically  
appropriate.  Refer to Section [IP_ADDRESS] and Section 4.1.17  for additional information and 
monitoring guidance for viral hepatitis and Section [IP_ADDRESS]  for additional information and 
management guidance for signs and symptoms of PML.  
[IP_ADDRESS] Hepatitis B Virus Reactivation 
Serious or life-threatening reactivation of viral hepatitis may occur in subjects treated with 
acalabrutinib .  Therefore, subjects who are hepatitis B core antibody (anti-HBc) positive or 
have a known history of hepatitis B virus ( HBV) infection, should be monitored monthly with 
a quantitative PCR  test for HBV DNA.  Monthly monitoring should continue until [ADDRESS_473281] with a rising viral load (above lower limit of 
detection) should discontinue acalabrutinib  and have antiviral therapy instituted and a 
consultation with a physician with expertise in managing hepatitis B.  Insufficient data exist 
regarding the safety of resuming acalabrutinib in subjects who develop HBV reactivation.   
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 39 [IP_ADDRESS] Progressive Multifocal L eukoencephalopathy  
Cases of progressive multifocal leukoencephalopathy (PML) have occurred in clinical 
studies with acalabrutinib.  Signs and symptoms of PML may include cognitive and 
behavioral changes, language disturbances, visual disturbances, sensory deficits, 
weakness, and coordination and gait difficulties. 
If PML is suspected, hold further treatment with acalabrutinib treatment until PML is 
excluded.  A diagnostic evaluation may include (but is not limited to): 
 Neurologic consultation 
 Brain magnetic resonance imaging (MRI) 
 PCR analysis for John Cunningham virus DNA in cerebrospi[INVESTIGATOR_223210], permanently discontinue acalabrutinib. 
3.7.[ADDRESS_473282] frequent second primary malignancy was 
skin cancer (basal cell carcinoma).  Subjects should be monitored for signs and symptoms 
of malignancy.  For Subjects who develop a second primary malignancy, subjects should 
be managed according to institutional guidelines with diagnostic evaluations as clinically 
indicated, and it may be necessary for subjects to permanently discontinue study treatment.  
Continuation of acalabrutinib treatment should be discussed with the medical monitor.  
Please refer to Section 6.2.3  for second primary malignancy reporting guidance. 
3.7.7 Atrial Fibrillation 
Events of atrial fibrillation/flutter have occurred in clinical studies with acalabrutinib 
particularly in subjects with cardiac risk factors, hypertension, diabetes mellitus, acute 
infections, or a previous history of atrial fibrillation. 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 40 Monitor for symptoms of atrial fibrillation and atrial flutter (e .g., palpi[INVESTIGATOR_814], dizziness, 
syncope, chest pain, dyspnea) and obtain an ECG as clinically indicated .  Subjects with 
atrial fibrillation should be managed per institutional guidelines with supportive care and 
diagnostic evaluations as clinically indicated .  
3.7.[ADDRESS_473283] generation Btk inhibitor, ibrutinib 
(IMBRUVICA® package insert ).  As a precaution, it is sugge sted that acalabrutinib  be held  
for 3 days before and after any major surgical procedure . 
3.7.9  Reproductive Toxicity  
Definition of Women of Non -reproductive Potential  
Women will be considered of non-reproductive potential if they are either:  
1) Postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in wome n <45 years of age a high follicle stimulating hormone (FSH) level 
in the post -menopausal rang e may be used to confirm a post -menopausal state in women 
not using hormonal contraception or hormonal replacement therapy.   In the absence of 
12 months of amenor rhea, a single FSH measurement is insufficient.);  
OR  
2) Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpi[INVESTIGATOR_176715]/occlusion, at least 6 weeks prior to screening;  
OR  
3) Have a congenital or acquired condi tion that prevents childbearing.  
Highly Effective Methods of Contraception‡  
Highly effective methods of contraception (to be used during heterosexual activity) are 
defined as methods that can achieve a failure rate of <1% per year when used consistently 
and correctly.  Such methods include:  
 Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation, which may be oral, intravaginal, or transdermal  
 Progestogen -only hormonal contraception associated with in hibition of ovulation, which 
may be oral, injectable, or implantable  
 Intrauterine device (IUD) or intrauterine hormone -releasing system (IUS)  
 Bilateral tubal occlusion  
 Vasectomy of a female subject’s male partner (with medical assessment and 
confirmatio n of vasectomy surgical success)  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 41  Sexual abstinence (only if refraining from heterosexual intercourse during the entire 
period of risk associated with the study treatments)  
 
Hormonal contraception may be susceptible to interaction with study or other drugs, which 
may reduce the efficacy of the contraception method.  
Periodic abstinence† (eg, calendar, ovulation, sympto-thermal, and post-ovulation methods) 
and withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method 
(LAM) are not acceptable methods of contraception.  Female condom and male condom 
should not be used together as an effective method of contraception.  
†Abstinence (relative to heterosexual activity) can only be used as the sole method of 
contraception if it is consis tently employed as the subject’s preferred and usual lifestyle and 
if considered acceptable by [CONTACT_378146]/IRBs.  Periodic abstinence 
(eg, calendar, ovulation, sympto-thermal, and post-ovulation methods) and withdrawal are 
not acceptable methods of contraception.  
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, then it 
does not qualify as an acceptable method of contraception for subjects participating at sites 
in this country/region. 
Developmental and reproductive toxicology studies in rats have not identified acalabrutinib-
related toxicities for fertility, reproductive success, embryofetal development, or embryofetal 
survival.  In rabbits, at dose levels which resulted in maternal toxicities, skeletal variations 
were associated with reductions in fetal weights.  Effects on parturition and post-natal 
development are pending.  For additional details, refer to the Acalabrutinib Investigator 
Brochure. 
Subjects should promptly notify the investigator if they, or their partners, become pregnant 
during this period.  Female subjects must also notify the investigator if they become 
pregnant within [ADDRESS_473284]’s partner must be reported as described in  
Section 6.2.4.  
3.7.[ADDRESS_473285]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 42 and vital signs and biochemical and hematologic parameters should be followed closely 
(consistent with the protocol or more frequently, as needed).  Appropriate supportive 
management to mitigate adverse effects should be initiated.  If the overdose ingestion is 
recent and substantial, and if there are no medical contraindications, use of gastric lavage 
or induction of emesis may be considered. 
The Acerta Pharma medical monitor should be contact[CONTACT_35114] a study drug overdose occurs.  
3.8 STOPPI[INVESTIGATOR_378119] .  However: 
 Any subject has the right to withdraw from the study at any time. 
 Any subject who has objective evidence of definitive DLBCL progression while receiving 
study treatment at the highest individual tolerable dose level allowed in the protocol  
(see Section 3.5.5 ) should be withdrawn from the study treatment.  Note: If there is 
uncertainty regarding whether there is DLBCL progression, the subject should continue 
study treatment and remain under close observation (eg, evaluated at 4- to 8-week 
intervals) pending confirmation of progression.  In particular, transient worsening of 
disease during temporary interruption of study therapy (eg, for intercurrent illness , 
drug-related toxicity, or surgery) may not indicate disease progression.  In such 
circumstances, and if medically appropriate, subjects may resume therapy and relevant 
clinical, laboratory, and/or radiographic assessment should be done  to document 
whether tumor control can be maintained or whether actual disease progression has 
occurred.  
 Any subject who is unable to tolerate rechallenge with the lowest protocol-described, 
dose-modified levels (see Section 3.5.5 ) should be withdrawn from the study treatment 
unless continued therapy is permitted by [CONTACT_378147]. 
 Any subject whose medical condition substantially changes after entering the study 
should be carefully evaluated by [CONTACT_378148].  Such subjects should be withdrawn from study treatment if continuing 
would place them at risk.  
 Any subject who becomes pregnant or begins breastfeeding should be removed from 
study treatment. 
 Any subject who becomes significantly noncompliant with study drug administration, 
study procedures, or study requirements should be withdrawn from study treatment in 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 43 circumstances that increase risk or substantially compromise the interpretation of study 
results. 
 The investigator, in consultation with the Acerta Pharma medical monitor, may withdraw 
any subject from the study treatment, if, in the investigator’s opi[INVESTIGATOR_1649], it is not in the 
subject’s best interest to continue.  
Subjects who discontinue study therapy will continue on study for safety ( Section 4.3) and 
time- to-next therapy ( Section 4.4) unless they withdraw consent for further follow- up.  
Thus, all subjects receiving ≥[ADDRESS_473286] is withdrawn from study treatment or from the study (including long-term 
follow-up) and the reason for discontinuation will be recorded and also should be described 
on the appropriate eCRF.   
3.9 DATA AND SAFETY MONITORING 
This trial will be monitored in accordan ce with the sponsor’s Pharmacovigilance Committee 
procedures.  Adverse events and SAEs will be reviewed internally on an ongoing basis to 
identify safety concerns.  Quarterly conference calls with the investigators will be conducted 
to discuss study progress, obtain investigator feedback and exchange, and discuss 
"significant safety events" (ie, AEs leading to dose reductions, related SAEs, and deaths).   
4.[ADDRESS_473287]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473288] read, understand and sign the IRB/IEC approved ICF confirming his or 
her willingness to participate in this study before initiating any screening activity that is not 
standard of care.  Subjects must also grant permission to use protected health information. 
4.1.[ADDRESS_473289]’s c omplete history through review of medical records and by 
[CONTACT_30230].  Concurrent medical signs and symptoms must be documented to establish 
baseline severities.  A disease history, including the date of initial diagnosis and list of all 
prior anticancer treatments, and responses to these treatments, also will be recorded. 
4.1.[ADDRESS_473290] available archival tissue for central pathology review.  Either 
unstained slides (minimum of 10 slides) or a paraffin block will be acceptable for central 
pathology review.  Please refer the study manual for a more detailed description of the 
procedures and for information on where to send the archival tissue samples. 
4.1.[ADDRESS_473291]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 45 4.1.8 Physical Examination, Vital Signs, Height & Weight 
The screening physical examination will include, at a minimum, the general appearance of 
the subject, height (screening only) and weight, and examination of the skin, eyes, ears, 
nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous system, 
and lymphatic system. 
Symptom-directed physical exams, including tumor assessments by [CONTACT_23302], will be done 
during the treatment period and at the safety follow-up visits. 
Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature) will be 
assessed after the subject has rested in the sitting position.    
4.1.[ADDRESS_473292] therapy for DLBCL may 
use those bone marrow results in lieu of the baseline bone marrow aspi[INVESTIGATOR_337]/biopsy required 
for this study provided the biopsy/aspi[INVESTIGATOR_378120] [ADDRESS_473293] dose of 
study drug.  Per the current response criteria ( Cheson  2014), a bone marrow 
aspi[INVESTIGATOR_337]/biopsy will also be required at any time on study to confirm complete remission 
(CR).  A bone marrow aspi[INVESTIGATOR_378121] 12.  Testing will 
be performed at the study center’s local laboratory or other clinical laboratory listed on the 
investigator’s form FDA 1572.   De-identified copi[INVESTIGATOR_378122]/aspi[INVESTIGATOR_378123].  
4.1.10 Electrocardiogram 
Subjects should be in supi[INVESTIGATOR_378124] ≥ [ADDRESS_473294] include complete blood count (CBC) with differential and platelet 
and reticulocyte counts.  Testing will be done by [CONTACT_2237]. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473295], bicarbonate, blood urea 
nitrogen (BUN), calcium, chloride, creatinine , glucose, lactate dehydrogenase ( LDH), 
magnesium, phosphate, potassium, sodium, total bilirubin, total protein, and uric acid.  If an 
unscheduled ECG is done at any time, then an electrolyte panel (ie, calcium, magnesium, 
and potassium) must be done to coincide with the ECG testing.  Testing will be done by [CONTACT_19979]. 
4.1.14 Urinalysis 
Urinalysis includes pH, ketones, specific gravity, bilirubin, protein, blood, and glucose.  
Testing will be done by [CONTACT_2237].  
4.1.15 T/B/NK Cell Count 
Flow cytometry testing will include CD3+, CD4+, CD8+, CD19+, and CD16/56+ cells.  Testing 
will be done by [CONTACT_2237]. 
4.1.[ADDRESS_473296] include hepatitis B surface antigen (HBsAg), hepatitis B 
surface antibody (HBsAb), anti-HBc, and hepatitis C (HCV) antibody.  Since intravenous 
immunoglobulins (IVIG) may cause false positive hepatitis serology, subjects who are 
receiving prophylactic IVIG and have positive HBsAg or anti-HBc must have negative 
hepatitis B DNA to be eligible.  In addition, any subjects testing positive for any hepatitis 
serology, must have PCR testing (see  Appendix 4  and exclusion criterion #13).  Testing will 
be done by [CONTACT_169617].   
Refer to Section [IP_ADDRESS]  and Appendix [ADDRESS_473297] a known history of HBV. 
4.1.18 Pharmacodynamics 
Blood samples will be used for PD testing (eg, Btk occupancy and B-cell activation).  Refer 
to the laboratory binder for instructions on collecting and processing these samples.   
Testing will be done by [CONTACT_456]. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 47 4.1.19 Pharmacokinetics 
Refer to the laboratory manual for instructions on collecting and processing these samples.  
Testing will be performed at a central clinical laboratory.  Leftover plasma samples may be 
used for exploratory acalabrutinib  metabolite analyses.  The predose sample can be taken 
up to 1 hour before dosing.   
Table 4-1.  Pharmacokinetic Sample Schedule 
 HOURS POSTDOSE  
Cycle  Day Predose  0.5 
(±5 min)  1 
(±5 min)  2 
(±5 min)  4 
(±10 min)  6 
(±10 min)  24 
(±30 min)  
1 1 X X X X X X X*before 
Day [ADDRESS_473298] 
dose  
 8 X X X X X X  
 15, 
22, 
28 Predose 
and 1 h 
(±5 min) 
postdose 
and 5 to 
15 min 
before 
electrocar
diogram  
(ECG)        
Note: All timepoints are relative to the morning dose. 
 
4.1.[ADDRESS_473299] (unless contraindicated) is required of the chest, 
abdomen, and pelvis and any other disease sites (eg, neck) within [ADDRESS_473300] 
dose of study drug.  A pretreatment positron-emission tomography (PET)/CT scan within 
[ADDRESS_473301] (unless contraindicated) of the chest, abdomen, 
and pelvis and any other disease sites (eg, neck) will be done for tumor assessments at the 
end of Cycle 2 (± 7 days), Cycle 4 (± 7 days), and Cycle 6 (± 7 days); and then every 
3 cycles (12 weeks, ± 7 days) thereafter or more frequently at investigator discretion.  
On-study tumor assessments will also be done by [CONTACT_378149].  
Bone marrow and PET/CT are only required for confirmation of CR per clinical guidelines 
(see Section 4.2).  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 48 Note: For sites in [LOCATION_013], radiologic tumor assessments will not include PET.  Radiologic 
tumor assessments will be done at Screening and at the end of Cycle 2 (± 7 days)  OR 
Cycle 4 (± 7 days) depending each on subjects’ individual response; thereafter they will be 
done at investigator discretion.  On-study  tumor assessments will also be done by [CONTACT_378150] d laboratory results.   
De-identified copi[INVESTIGATOR_378125].    
Subjects should have radiographic tumor measurements done at the participating study 
center or an acceptable alternate imaging facility using an identic al imaging protocol and 
similar equipment.  The same imaging equipment should be used for all scans whenever 
possible.  The same radiologist should be assigned to read all the scans for a given subject 
throughout the study.  
In the event disease progressio n is suspected due to physical examination or laboratory 
test, a CT and PET/CT scan must be performed to confirm disease progression.   There 
must be radiographically measurable disease at screening (≥ 1 lymph node > 2.[ADDRESS_473302] diameter).   If the sole lesion lies within the field of prior radiotherapy, there must be 
evidence of disease progression in that lesion.  
Up to 6 measurable lymph nodes (only target lesions > 1.[ADDRESS_473303] diameter may 
be assessed), clearly measurable in [ADDRESS_473304]’s disease.   In addition,  selection of target lesions should be 
from as disparate regions of the body as possible when these areas are significantly 
involved.  If additional lesions are present but are not included in the target lesion 
assessment, they can be added as non-target l esions followed throughout the study.  The 
cranial -caudal measurement of the spleen and longest diameter of the liver will be 
assessed at screening and all subsequent response evaluations.  
4.1.[ADDRESS_473305]  and/or PET/CT  scan is not obtained.  The investigator should report 
any suspected disease progression to t he sponsor or designee via the electronic data 
capturing (EDC) system within [ADDRESS_473306]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 49 4.1.22 Study Drug Accountability 
See Section 7.7. 
4.2 INVESTIGATOR’S ASSES SMENT OF RESPONSE TO TREATMENT 
The investigator must rate the response of the subject’s response to treatment consistent 
with clinical guidelines ( Cheson  2014) as listed in Table 4-[ADDRESS_473307]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 50 Table 4-2.  Response Assessment Criteria for DLBCL ( Cheson  2014) 
Response and Site  PET-CT-Based Response  CT-Based Response  
Complete  Complete metabolic response  Complete radiologic response (all of the 
following)  
 Lymph nodes and 
extra lymphatic sites  Score 1, 2, or 3* with or without a 
residual mass on 5PS  
It is recognized that in Waldeyer’s ring or 
extranodal sites with high physiologic 
uptake or with activation within spleen or 
marrow (eg, with chem otherapy or 
myeloid colony -stimulating factors), 
uptake may be greater than normal 
mediastinum and/or liver.  In this 
circumstance, complete metabolic 
response may be inferred if uptake at 
sites of initial involvement is no greater 
than surrounding normal tissue even if 
the tissue has high physiologic uptake  Target nodes/nodal masses must regress 
to ≤1.5 cm in LDi  
No extralymphatic sites of disease  
 Nonmeasured lesion  Not applicable  Absent  
 Organ enlargement  Not applicable  Regress to normal  
 New lesions  None  None  
 Bone marrow  No evidence of FDG -avid dise ase in the 
marrow  Normal by [CONTACT_5293]; if indeterminate, 
IHC negative  
Partial  Partial metabolic response  Partial remission (all of the following)  
 Lymph nodes and 
extra lymphatic sites  Score 4 or5 with reduced uptake 
compared with baseline and residu al 
mass(es) of any size  
At interim, these findings suggest 
responding disease  
 
At end of treatment, these findings 
indicate residual disease  ≥ 50% decrease in SPD of up to [ADDRESS_473308], assign 5 mm ×5 mm as the default 
value  
When no longer visible, 0 × 0mm  
For a node > 5 mm × 5 mm, but smaller 
than the normal, use ac tual measurement 
for calculation  
 Nonmeasured 
lesions  Not applicable  Absent/normal, regressed, but no increase  
 Organ enlargement  Not applicable  Spleen must have regressed by > 50% in 
length beyond normal  
 New lesions  None  None  
 Bone marrow  Residua l uptake higher than uptake in 
normal marrow but reduced compared 
with baseline (diffuse uptake compatible 
with reactive changes from 
chemotherapy allowed).  If there are 
persistent focal changes in the marrow in 
the context of a nodal response, 
considerat ion should be given to further 
evaluation with MRI or biopsy or an 
interval scan  Not applicable  
Footnotes appear after the last page of the table. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 51  
Table 4-2.  Response Assessment Criteria for DLBCL ( Cheson 2014 ) (continued) 
Response and Site  PET-CT-Based Response  CT-Based Response  
No response or stable 
disease  No metabolic response  Stable disease  
 Target nodes/nodal 
masses, extranodal 
lesions  Score 4 or 5 with no significant change in 
FDG uptake from basel ine at interim or 
end of treatment  < 50% decrease from baseline in SPD of 
up to 6 dominant, measurable nodes and 
extranodal sites; no criteria for progressive 
disease are met  
 Nonmeasured 
lesions  Not applicable  No increase consistent with progression  
 Organ enlargement  Not applicable  No increase consistent with progression  
 New lesions  None  None  
 Bone marrow  No change from baseline  Not applicable  
Progressive disease  Progressive metabolic disease  Progressive disease requires at least 1 of 
the followi ng  
 Individual target 
nodes/nodal masses  Score 4 or 5 with increase in intensity of 
uptake from baseline and/or  
 [COMPANY_003] progression:  
 Extranodal lesions  New FDG -avid foci consistent with 
lymphoma at interim or end -of-treatment 
assessment  An individual node /lesion must be 
abnormal with:  
LDi > 1.5 cm and  
Increase by ≥ 50% from [COMPANY_003] nadir and  
An increase in LDi or SDi from nadir  
0.5 cm for lesions ≤ 2cm  
1.0 cm for lesions > [ADDRESS_473309] increase by > 50% of the 
extent of its prior increase beyond baseline 
(eg, a 15-cm spleen must increase to >16 
cm).  If no prior splenomegaly, must 
increase by [CONTACT_2669] 2 cm from baseline  
New or recurrent splenomegaly  
 Nonmeasured 
lesions  None  New or clear progression of preexisting 
nonmeasured lesions  
 New lesions  New FDG -avid foci consistent with 
lymphoma rather than another etiology 
(eg, infection, inflammation).  If uncertain 
regarding etiology of new lesions, biopsy 
or interval scan may be considered  Regrowth of previously resolved lesions  
A new node > 1.5 cm in any axis  
A new extranodal site >1.0 cm in any axis; 
if < 1.[ADDRESS_473310] be attributable to 
lymphoma  
Assessable disease of any size 
unequivocally attributable to lymphoma  
 Bone marrow  New or recurrent FDG -avid foci  New or recurrent involvement  
Abbreviations: 5PS, 5-point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, 
immunohistochemistry; LDi, longest transverse diameter of a lesion; MRI, magnetic resonance imaging; PET 
positron emission tomography; [COMPANY_003], cross product of the LDi and perpendicular diameter; SDi, shortest axis 
perpendicular to the LDi; SPD, sum of the product of the perpendicular diameters for multiple lesions. 
*A score of [ADDRESS_473311]: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 52 consider a score of 3 as inadequate response (to avoid undertreatment).  Measured dominant lesions: Up to six 
of the largest dominant nodes, nodal masses, and extranodal lesions selected to be clearly measurable in two 
diameters.  Nodes should preferably be from disparate regions of the body and should include, where 
applicable, mediastinal and retroperitoneal areas .  Non-nodal lesions include those in solid organs (eg, liver, 
spleen, kidneys, and lungs), GI involvement, cutaneous lesions, or those noted on palpation.  Nonmeasured 
lesions: Any disease not selected as measured, dominant disease and truly assessable disease should be 
considered not measured.  These sites include any nodes, nodal masses, and extranodal sites not selected as 
dominant or measureable or that do not meet the requirements for measurability but are still considered 
abnormal, as well as truly assessable disease, which is any site of suspected disease that would be difficult to 
follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal 
disease, abdominal masses, and other lesions that cannot be confirmed and followed by [CONTACT_9661].  In 
Waldeyer’s ring or in extranodal sites (eg, GI tract, liver, bone marrow), FDG uptake may be greater than in the 
mediastinum with complete metabolic response, but should be no higher than surrounding normal physiologic 
uptake (eg, with marrow activation as a result of chemotherapy or myeloid growth factors).  
 PET 5PS: 1, no upta ke above background; 2. Uptake ≤ mediastinum; 3, uptake > mediastinum but ≤ liver; 4, 
uptake moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake 
unlikely to be related to lymphoma.  
 
4.3 EARLY TERMINATION/SAFETY FOLLOW-UP VISIT 
An early termination visit is required for any subjects who permanently discontinue study 
drug early for any reason including disease progression.  Each subject should be followed 
for 30 (±7) days after his or her last dose of study drug (ie, the “safety follow -up visit”) to 
monitor for resolution or progression of AEs (see Section 6.2.6 ) and to document the 
occurrence of any new events, unless the subject receives a new anticancer therapy within 
this timeframe.  Subjects who withdraw consent should still be encouraged to complete the 
safety follow-up assessments, but these assessments cannot be mandated once consent is 
withdrawn.  The Schedule of Assessments ( Appendix 4 ) describes the procedures required 
for the safety follow-up.  
4.4 TIME- TO-NEXT TREATMENT 
Subjects who discontinue study therapy will continue on study for follow-up of safety 
(Section 4.3) and time- to-next DLBCL therapy unless they withdraw consent for further 
follow- up.  Thus, all subjects receiving ≥  [ADDRESS_473312] is withdrawn from the 
study and the reason for discontinuation will be recorded and also should be described on 
the appropriate electronic case report form (eCRF).   
4.[ADDRESS_473313]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 53 investigator’s opi[INVESTIGATOR_1649], medically unnecessary or unsafe because it is too close in time to 
the next scheduled evaluation .  In that case , the missed evaluation should be abandoned.  
5.0 STATISTICAL METHODS OF ANALYSIS  
5.1 GENERAL CONSIDERATIO NS 
This proof -of-concept study is designed to assess the safety, PK/PD, and activity of 
acalabrutinib  100 mg BID in subjects with relapsed/refr actory de novo ABC DLBCL.  
5.1.1  Response Assessment  
Response assessments will be done by [CONTACT_473] . 
5.1.2  Safety Monitoring  
The safety plan includes quarter ly conference calls between Acerta  and investigators to 
discuss study -specific issues including adverse events and serious adverse events.   
5.2 DEFINITION OF ANALYS IS SETS  
The following definitions will be used for the efficacy and safety analysis sets.  
Safety analysis set: All enrolled subjects who receive ≥  1 dose of study drug.  
Per-protocol (PP) analysis set : All enrolled subjects who receive ≥  [ADDRESS_473314] sufficient baseline measurements,  and und ergo ≥ [ADDRESS_473315] (eg, response and PK/PD parameters) after treatment.  
Intent -to-treat (ITT) population : All subjects w ho have enrolled in the protocol.  
The safety analysis set will be used for evaluating the safety and efficacy, except duration 
of response, parameters in this study.  The PP and ITT analysis sets will be analyzed for 
efficacy and PK/PD parameters in this s tudy.  
5.3 MISSING DATA HANDLIN G 
General Considerations:   Subjects lost to follow -up (or who dropped out) will be included 
in statistical analyses up to the point of their last evaluation.  
Duration of Response and Progression -free Survival:   Data for subjects w ithout disease 
progression or death will be censored at the date of the last tumor assessment and before 
the initiation of alternative anticancer therapy.  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 54 Safety:   Missing or partial start and end dates for AEs and concomitant medications will be 
imputed a ccording to prespecified, conservative imputation rules.  No other imputation of 
values for missing data will be performed.  
5.4 DETERMINATION OF SAM PLE SIZE  
No formal statistical tests of hypotheses will be performed.  Descriptive statistics  (including 
means,  standard deviations, and medians for continuous variables and  proportions for 
discrete variables) will be used to summarize data as appropriate.  
The trial design is specified because of its  practical simplicity, use of a biomarker, and not 
because of powe r considerations.   The sample size of 20 subjects in a Phase 1b study is 
considered adequate to evaluate the initial safety, PK/PD, and activity of acalabrutinib  in 
this patient population.  
5.5 DATA ANALYSIS  
5.5.1  Safety Parameters  
Safety summaries will include summ aries in the form of tables and listings.  The frequency 
(number and percentage) of treatment emergent AEs will be reported in each t reatment 
group by [CONTACT_61125].  Summaries will also be 
presented by [CONTACT_378151] (per CTCAE, v4.03)  and by [CONTACT_8792].  
Laboratory shift tables containing counts and percentages will be prepared by [CONTACT_11512], laboratory parameter, and time.  Summary tables will be prepared for each 
laboratory parameter.  Figu res of changes in laboratory parameters over time will be 
generated.  
Results of vital sign assessments , ECGs, and physical exams will be tabulated and 
summarized.   
5.5.[ADDRESS_473316] demographics, baseline 
characteristics, compliance, and concurrent treatments.  Concomitant medications will be 
coded according to the World Health Organization (WHO) Drug Dictionary and tabulated.  
5.5.[ADDRESS_473317]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 55 For each patient , acala brutinib  compliance  will be described in terms of the proportion of 
study drug actually taken based on returned pi[INVESTIGATOR_378126] (taking into account physician -prescribed modifications  and interruptions).  
5.5.4  Analysis of Eff icacy Parameters  
Response Rate  
The individual and composite endpoints of response and progression will  be determined.  
Tumor control will be documented at each assessment by [CONTACT_115188] (eg, CR, PR, 
SD, PD) as defined for each response parameter , date that re sponse is first documented, 
and date of DLBCL  disease progression . 
Overall response rate  will be defined as the proportion of subjects who achieve a CR or 
PR.  Overall response rate  will be calculated and the correspo nding 97.5%  one-sided  
confiden ce interval will be derived.  
Duration of Response  
The duration of response (DOR) defined as the interval from the first documentation of CR  
or PR  to the earlier of the first documentation of definitive disease progression or death 
from any cause .  Kaplan -Meier methods  will be used to estimate event -free curves and 
corresponding quantiles (including the median).   Data from surviving, nonprogressing 
subjects will be censored at the earliest of the time of initiation of anticancer  treatment other 
than the stud y treatment or the last t ime that lack of definitive DLBCL  progression was 
objectively documented.  Data from subjects who have DLBCL  progression or die after 
≥ [ADDRESS_473318] time before  the 
missing as sessments that lack of DLBCL  progression was objectively documented.  
Progression -free Survival  
Progression -free survival (PFS) is defined as the interval from the start of acalabrutinib  
therapy to the earlier of the first documentation of objective DLBCL  disease progr ession or 
death from any cause .  Kaplan -Meier methods  will be used to estimate the event -free 
curves and corresponding quantiles (including the median).   Data from surviving, 
non-progressing subjects will be censored at the earliest of the time  of initiation of 
anticancer  treatment other than the study treatment or the last time that lack of DLBCL  
progression was objectively documented.  Data from subjects who have DLBCL  
progression or die after  ≥ [ADDRESS_473319]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473320] time prior to the missing assessments that lack of FL progression was objectively 
documented.  
Time -to-Next Treatment  
Time -to-next treatment defined as the time from start of acalabrutinib  therapy  for DLBCL  on 
this protocol to the start  of the next treatment for DLBCL .  Kaplan -Meier methods will be 
used to estimate the event -free curves and corresponding quantiles (including the median).  
Data from subjects who have not received subsequent therapy for DLBCL  will be censored 
at the earlie st of death or the last time that lack of administration of a new therapy for 
DLBCL  was objectively documented.  
5.5.5  Analysis of Pharmacokinetic/Pharmacodynamic Parameters   
The plasma PK of acalabrutinib  will be characterized using noncompartmental analysis.  
The following PK parameters will be calculated, whenever possible, from plasma 
concentrations of acalabrutinib : 
 AUC 0-t Area under the plasma concentration -time curve calculated using 
linear trapezoidal summation from time [ADDRESS_473321] measurable concentration (C t). 
 AUC 0-12 Area under the plasma concentration -time curve from 0 to  12 hours, 
calculated using linear trapezoidal summation.  
 AUC 0-∞ Area under the plasma concentration -time curve from 0 to infinity, 
calculated using th e formula: AUC 0-∞ = AUC 0-t + C t / λz, where λ z is the 
apparent terminal elimination rate constant.  
 AUC 0-24calc Area under the plasma concentration -time curve from 0 to  24 hours, 
calculated by [CONTACT_378152] 0-12. 
 Cmax Maximum observed plasma con centration  
 Tmax Time of the maximum plasma concentration (obtained without 
interpolation)  
 t½ Terminal elimination half -life (whenever possible)  
 λz Terminal elimination rate constant (whenever possible)  
 CL/F Oral clearance  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473322] change from 
baseline during the study will also be summarized.  As appropriate, the on-treatment values 
will be compared with the pretreatment baseline values using paired t-tests.  P-values of 
 0.[ADDRESS_473323] of monitoring and recording AEs and SAEs ; measurements 
of protocol-specified hematology, clinical chemistry, urinalysis, and other laboratory 
variables; measurement of protocol-specified vital signs; and other protocol-specified tests 
that are deemed critical to the safety evaluation of the study drug(s). 
6.1 DEFINITIONS 
6.1.1 Adverse Events 
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated 
with the use of an investigational (medicinal) product or other protocol-imposed 
intervention, regardless of attribution. 
This includes the following: 
 AEs not previously observed in the subject that emerge during the protocol-specified 
AE reporting period, including signs or symptoms associated with DLBCL that were not 
present before the AE reporting period (see Section 6.2.1 ) 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 58  Complications that occur as a result of protocol -mandated interventio ns (eg, invasive 
procedures such as biopsies)  
 Preexisting medical conditions (other than the condition being studied) judged by [CONTACT_51754] -specified AE reporting pe riod. 
Abnormal laboratory values should not be reported as AEs; however, any clinical ly 
significant laboratory values (defined as  requiring treatment, discontinuation from the study , 
or dose modification ) should be reported as AEs. 
6.1.2  Serious Adverse Event  
The terms “ severe ” and “serious” are not synonymous.  Severity (or intensity) refers to the 
grade of an AE (see below).  “Serious” is a regulatory definition and is based on subject or 
event outcome or action criteria usually associated with events that pose  a threat to a 
subject’s life or functioning.  Seriousness (not severity) serves as the guide for defining 
regulatory reporting obligations from the sponsor to applicable regulatory authorities.  
An AE should be classified as an SAE if it meets any 1 of the  following criteria:  
 It results in death (ie, the AE actually causes or leads to death).  
 It is life -threatening (ie, the AE, in the view of the investigator, places the subject at 
immediate risk of death.  It does not include an AE that, had it occurred in  a more 
severe form, might have caused death).  
 It requires or prolongs in -patient hospi[INVESTIGATOR_059].  
 It results in persistent or significant disability/incapacity (ie, the AE results in substantial 
disruption of the subject’s ability to conduct normal life f unctions).  
 It results in a congenital anomaly/birth defect in a neonate/infant born to a mother 
exposed to the investigational product.  
 It is considered a significant medical event by [CONTACT_188212] (eg, may jeopardize the subje ct or may require medical/surgical intervention 
to prevent 1 of the outcomes listed above).  
6.1.3  Severity  
Definitions found in the CTCAE  version 4.0 3 or higher  will be used for grading the severity 
(intensity) of AEs.  The CTCAE  displays Grades [ADDRESS_473324] experience any AE not 
listed in the CTCAE , the following g rading system should be used to assess severity:  
 Grade 1 (Mild AE) – experiences which are usually transient, requ iring no special 
treatment, and not interfering with the subject’s daily activities  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 59  Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience 
or concern to the subject, and which may interfere with daily activities, but are 
usually ameliorated by [CONTACT_14212] 
 Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, 
significantly interrupt the subject’s usual daily activity, and require systemic drug 
therapy or other treatment 
 Grade 4 (Life-threatening or disabling AE) – experiences which cause the subject to 
be in imminent danger of death 
 Grade 5 (Death related to AE) – experiences which result in subject death 
 
6.1.[ADDRESS_473325] (AESIs) and must be reported 
to the sponsor expeditiously (see Section 6.2 for reporting instructions), irrespective of 
regulatory seriousness criteria or causality: 
 Ventricular arrhythmias (e.g., ventricular extrasystoles, ventricular tachycardia, 
ventricular arrhythmia, ventricular fibrillation) 
 
6.[ADDRESS_473326] be reported on the SAE/Product Compliant form (see Section 6.2.5 ). 
6.2.[ADDRESS_473327] dose of study drug, all AEs/SAEs, irrespective of attribution of 
causality, must be reported.  
All adverse events will be reported until [ADDRESS_473328] dose of study drug or the start 
of new anticancer therapy (whichever comes first).  After this period, investigators should 
report serious adverse events or other adverse events of concern that are believed to be 
related to prior treatment with study drug. 
All SAEs that occur during the reporting period should be followed to resolution or until the 
Investigator assesses the subject as stable or until the subject is lost to follow-up or 
withdraws consent.  Resolution/stable means the subject has returned to baseline state of 
health or the investigator does not expect any further improvement or worsening of the 
event. 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473329]’s medica l record and on the AE 
eCRF and, when applicable, on an SAE/Product Compliant form. 
Disease progression itself is not considered an AE; however, signs and symptoms of 
disease progression may be recorded as AEs or SAEs. 
Symptomatic deterioration may occur in some subjects.  Symptomatic deterioration is when 
progr ession is evident in the subject’s clinical symptoms and the investigator may elect not 
to perform further disease assessments. 
Each recorded AE or SAE will be described by [CONTACT_13662] (ie, start and end dates), 
severity, regulatory seriousness criteria, if applicable, suspected relationship to the study 
drug (see following guidance), and any actions taken.  The relationship of AEs to the study 
drug will be assessed by [CONTACT_7859]: ‘Is there a reasonable possibility that the 
event may have been c aused by [CONTACT_5257]?’  Answer Yes or No.  
See Appendix 3  for more detail on assessing relationship. 
6.2.3 Second Primary Malignancies 
Adverse events (AEs) for malignant tumors reported during a study should generally be 
assessed as serious AEs (SAEs).  If no other seriousness criteria apply, the “Important 
Medical Event” criterion should be used.   In certain situations, however, medical judgment 
on an individual event basis should be applied to clarify that the malignant tumor event 
should be assessed and reported as a nonserious AE.  For example, if the tumor is 
included as medical history and progression occurs during the study but the progression 
does not change treatment and/or prognosis of the malignant tumor, the AE may not fulfill 
the attributes for being assessed as serious, although reporting of the progression of the 
malignant tumor as an AE is valid and should occur.  Also, some types of malignant 
tumors, which do not spread remotely after a routine treatment that does not require 
hospi[INVESTIGATOR_059], may be assessed as nonserious; examples in adults include Stage 1 basal 
cell carcinoma and Stage 1A1 cervical cancer removed via cone biopsy. 
The above instruction applies only when the malignant tumor event in question is a new 
malignant tumor (i.e., it is not the tumor for which entry into the study is a criterion and that 
is being treated by [CONTACT_7198]  [IP] under study and is not the development 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 61 of new or progression of existing metastasis to the tumor under study).  Malignant tumors 
that—as part of normal, if rare, progression —undergo transformation (e.g., Richter's 
transformation of B cell chronic lymphocytic leukemia into diffuse large B cell lymphoma) 
should not be considered a new malignant tumor.    
6.2.[ADDRESS_473330] be reported 
using the SAE report form, according to the usual timelines and directions for SAE 
reporting ( Section 6.2.5 ). 
Any uncomplicated pregnancy that occurs in a study subject or a partner of a treated 
subject during this study will be reported for tracking purposes only, if agreed to by [CONTACT_378153].  All pregnancies and partner pregnancies 
that are identified during or after this study, where in the estimated date of conception is 
determined to have occurred from the time of consent to [ADDRESS_473331] interfered with the effectiveness of a contraceptive 
medication.  Likewise, elective abortions without complications are not considered AEs.  
Any SAEs associated with pregnancy (eg, congenital abnormalities/birth 
defects/spontaneous miscarriages or any other serious events) must additionally be 
reported as such using the SAE/Product Complaint form.  
Subjects should be instructed to immediately notify the investigator of any pregnancies.  
Any female subjects receiving acalabrutinib who become pregnant must immediately 
discontinue study drug.  The investigator should counsel the subject, discussing any risks 
of continuing the pregnancy and any possible effects on the fetus.   
6.2.[ADDRESS_473332] be reported within 24 hours of discovery.  All initial SAE /AESI  reports and 
follow-up information will be reported using the protocol-specific electronic data capture 
system.  If electronic SAE /AESI  reporting is not available, paper SAE/Product Complaint 
forms must be emailed or faxed to Acerta Pharma Drug Safety, or designee.  Acerta 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473333] follow-up and other additional information from the investigator 
(eg, hospi[INVESTIGATOR_063]/discharge notes and laboratory results).  
All deaths should be reported with the primary cause of death as the AE term, as death is 
typi[INVESTIGATOR_36069], not the event itself.  The primary cause of death on the 
autopsy report should be the term reported.  Autopsy and postmortem reports must be 
forwarded to Acerta Pharma Drug Safety, or designee, as outlined above. 
If study drug is discontinued because of an SAE/AESI , this information must be included in 
the SAE /AESI  report. 
An SAE /AESI  may qualify for mandatory expedited reporting to regulatory authorities if the 
SAE/AESI  is attributable to the investigational product and is not listed in the current 
Investigator Brochure (ie, an unexpected event).  In this case, Acerta Pharma Drug 
Safety/Designee will forward a formal notification describing the SAE /AESI  to all 
investigators.  Each investigator must then notify his or he r IRB/IEC of the SAE/AESI . 
Drug Safety Contact [CONTACT_378154]: 
Email:  
 
6.2.[ADDRESS_473334] to follow-up or withdraws consent. 
6.2.7 Hy’s Law  
Cases where a subject shows elevations in liver biochemistry may require further 
evaluation, and oc currences of AST or ALT ≥3×ULN together with total bilirubin ≥2×ULN 
may need to be reported as SAEs.  Refer to Appendix 5  for further instruction on cases of 
increases in liver biochemistry and evaluation of Hy’s law . 
7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS 
Acerta Pharma retains the right to terminate the study and remove all study materials from 
a study site at any time.  Specific circumstances that may precipi[INVESTIGATOR_378127]: 
 Unsatisfactory subject enrollment with regard to quality or quantity 
[COMPANY_003]
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 63  Significant or numerous deviations from study protocol requirements, such as failure 
to perform required evaluations on subjects and maintain adequate study records 
 Inaccurate, incomplete, or late data recording on a recurrent basis 
 The incidence and/or severity of AEs in this or other studies indicating a potential 
health hazard caused by [CONTACT_104841] 
7.1 REGULATORY AND ETHICAL COMPLIANCE 
This clinical study was designed and will be implemented in accordance with the protocol, 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practices, applicable local 
regulations (including US Code of Federal Regulations Title 21 and European Directive 
2001/20/EC), and the ethical principles laid down in the Declaration of Helsinki. 
7.[ADDRESS_473335] AND INDEPENDENT ETHICS 
COMMITTEE 
The investigator will submit this protocol, the ICF, Investigator Brochure, and any other 
relevant supporting information (eg, all advertising materials) to the appropriat e IRB/IEC for 
review and approval before study initiation.  A signed protocol approval page; a letter 
confirming IRB/IEC approval of the protocol and informed consent;  and a statement that the 
IRB/IEC is organized and operates according to GCP and the applicable laws and 
regulations;  must  be forwarded to Acerta Pharma before  screening subjects for the study.  
Additionally, sites must forward a signed FDA 1572 form (Statement of Investigator Form) 
to Acerta Pharma before screening subjects for study enrollment.  Amendments to the 
protocol must also be approved by [CONTACT_1201]/IEC and local regulatory agencies, as 
appropriate, before the implementation of changes in this study. 
7.[ADDRESS_473336] HEALTH 
INFORMATION AUTHORIZATION 
A copy of the IRB/IEC-approved ICF must be forwarded to Acerta Pharma for regulatory 
purposes.  The investigator, or designee (designee must be listed on the Study Personnel 
Responsibility/Signature [CONTACT_94618], see Section 7.12), must  explain to each subject the purpose 
and nature of the study, the study procedures, the possible adverse effects, and all other 
elements of consent as defined in § 21CFR Part 50, and other applicable national and local 
regulations governing informed consent.  Each subject must provide a signed and dated 
ICF before enrollment into this study.  In the case of a subject who is incapable of providing 
informed consent, the investigator (or designee) must obtain a signed and dated informed 
consent form from the s ubject’s legal guardian.  Signed consent forms must remain in each 
subject’s study file and be available for verification by [CONTACT_9534].  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-[ADDRESS_473337]’s protected health information obtained during the study may be shared with Acerta 
Pharma and its designees, regulatory agencies, and IRBs/IECs.  As the study Sponsor, 
Acerta Pharma will not use the subject’s protected health information or disclose it to a third 
party without applicable subject authorization.  It is the investigator’s or designee’s 
responsibility to obtain written permission to use protected health information from each 
subject, or if appropriate, the subject’s legal guardian.  If a subject or subject’s legal 
guardian withdraws permission to use protected health information, it is the investigator’s 
responsibility to obtain the withdrawal request in writi ng from the subject or subject’s legal 
guardian and to ensure that no further data will be collected from the subject.  Any data 
collected on the subject before withdrawal will be used in the analysis of study results. 
7.[ADDRESS_473338] that lists all subjects considered for enrollment 
(including those who did not undergo screening) in the study.  For those subjects 
subsequently excluded from enrollment, record the reason(s) for exclusion. 
7.5 CASE REPORT FORMS 
Authorized study site personnel (see Section 7.12) will complete eCRFs designed for this 
study according to the completion guidelines that will be provided.  The investigator will 
ensure that the eCRFs are accurate, complete, legible, and completed within [ADDRESS_473339]’s visit  (unless required earlier for SAE reporting).  The investigator will ensure 
that source documents that are required to verify the validity and completeness of data 
transcribed on the eCRFs are never obliterated or destroyed, in accordance with the record 
retention policies described in Section 7.8. 
7.[ADDRESS_473340]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 65 investig ator agrees to allow the IRB/IEC , representatives of Acerta Pharma , its designated 
agents, and authorized employees of the appropriate regulatory agencies to inspect the 
facilities u sed in this study and, for purposes of verification, allow direct access to the 
hospi[INVESTIGATOR_147443].  This includes providing by 
[CONTACT_6791], email, or regular mail de -identified copi[INVESTIGATOR_134464], pathology, and/o r laboratory 
results when requested by [CONTACT_456].  A statement to this effect will be included in the 
informed consent and permission form authorizing the use of protected health information.  
7.[ADDRESS_473341] be maintained and readily available for inspection 
by [CONTACT_378155].  
Each shipment of study drug  will contain  a Clinical Supplies Shippi[INVESTIGATOR_378128] (CSSF ) 
that must be appended to the site’s drug accountability records.  If it is used, the Dru g 
Re-order  Form (provided in the pharmacy  binder) must also be included in the site’s drug 
accountability records.    
Contents of each shipment must be visually inspected to verify the quantity and document 
the condition of study drug  capsules .  Then the designated recip ient completes and signs 
the CSSF.  A copy of the signed CSSF  must be faxed or emailed to Acerta Pharma  at the 
fax number/ emailing address listed on the form.  
An Investigational Drug Accountability Log must be used for drug accountability.  For 
accurate accountability, the following  information must be noted when drug supplies are 
used during the study:  
1. study identification number ( ACE-LY-002) 
2. subject  identification number  
3. lot number(s) of acalabrutinib  dispensed  for that subject  
4. date and quantity of drug dispensed  
5. any unused drug re turned by [CONTACT_378156], the monitor will evaluate and approve the site’s procedure for 
investigational product  disposal/destruction to ensure that it complies with Acerta Pharma ’s 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 66 requirements.  If the site cannot meet Acerta Pharma ’s requirements for 
disposal/destruction, arrangements will be made between the site and Acerta Pharma  or its 
representative, for return of unus ed investigational product.  Before  disposal/destruction, 
final drug accoun tability and reconciliation must  be perfo rmed by [CONTACT_222221]. 
All study  supplies and associated documentation will be regularly reviewed and verified by 
[CONTACT_2037].  
7.[ADDRESS_473342] RETENTION  
The investigator and other appropriate study staff are responsible for maintaining all 
documentation relevant to t he study.  Mandatory documentation includes copi[INVESTIGATOR_378129], each FDA Form 1572, IRB/IEC  approval letters, signed ICFs, 
drug accountability records, SAE forms  transmitted to Acerta Pharma , subject files (source 
documentation) that substantiate entries in eCRFs, and all relevant correspondence and 
other documents pertaining to the conduct of the study.  
An investigator shall retain records for a period of at least [ADDRESS_473343] 
marketing application is approved for t he drug for the indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for such 
indication, until [ADDRESS_473344] from the study site so that they can be returned 
sealed to the investigator for audit purposes.  
7.9 PROTOCOL AMENDMENTS  
Acerta Pharma  will initiate any change to the protocol in a protocol amendment do cument.  
The amendment will be submitted to the IRB/IEC  together with, if applicable, a revised 
model ICF.  If the change in any way increases the risk to the subject or changes the scope 
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma Confidential  Page 67 of the study, then written documentation of IRB/IEC approval must be received by [CONTACT_378157].  Additionally under this circumstance, 
information on the increased risk and/or change in scope must be provided to subjects 
already actively participating in the study, and they must read, understand, and sign any 
revised ICF confirming willingness to remain in the trial. 
7.[ADDRESS_473345].  The results may also be used for 
papers, abstracts, posters or other material presented at scientific meetings or published in 
professional journals or as part of an academic thesis by [CONTACT_2413].  The study is 
being conducted as part of a multicenter clinical trial.  Data from all study centers shall be 
pooled and analyzed for publication in a final report (Primary Publication).  The investigator 
agrees that the Primary Publication, which will be coordinated by [CONTACT_378158], will be 
the first publication to present the pooled study results.  After the Primary Publication, or if 
the Primary Publication is not published within [ADDRESS_473346] matter and/or any inadvertent disclosure of its 
confidential information, which must be redacted from any final publication or presentation.  
If necessary, to permit the preparation and filing of patent applications, Acerta Pharma may 
elect an additional review period not to exceed 60 days. 
Authorship, in general, will follow the recommendations of the International Committee of 
Medical Journal Editors (International Committee of Medical Journal Editors  2014) .   
7.[ADDRESS_473347]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473348] ensure that:  
1. He or she will personally conduct or supervise t he study.  
2. His or her staff and all persons who assist in the conduct of the study clearly 
understand their responsibilities and have their names included in the Study 
Personnel Responsibility/Signature [CONTACT_94618] . 
3. The study is conducted according to the protocol and all applicable regulations.  
4. The protection of each subject’s rights and welfare is maintained.  
5. Signed and dated informed consent and , when applicable,  permission to use 
protected health information are obtained from each subject before conducting 
nonst andard of care study procedures.  If a subject or subject’s legal guardian 
withdraws permission to use protected health information, the investigator will obtain 
a written request from the subject or subject’s legal guardian and will ensure that no 
further  data be collected from the subject.  
6. The consent process is conducted in compliance with all applicable regulations and 
privacy acts.  
7. The IRB/IEC  complies with applicable regulations and conducts initial and ongoing 
reviews and approvals of the study.  
8. Any amendment to the protocol is s ubmitted promptly to the IRB/IEC . 
9. Any significant protocol deviations are reported to Acerta Pharma  and the IRB/IEC  
according to the guidelines at each study site.  
10. Electronic CRF pages are completed within [ADDRESS_473349]’s visit  (unless 
required earlier for SAE reporting) . 
11. All IND Safety Reports /Suspected Unexpected S erious Adverse Reaction ( S[LOCATION_003]R ) 
Reports  are submitted promptly to the IRB/IEC . 
12. All SAEs are reported to Acerta Pharma  Drug Safety /Designee  within 24  hours  of 
knowledge and to the IRB/IEC  per their requirements.  
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 69 8.0 REFERENCES  
Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. 
Cell Signal 2010;22:1175 -84.  
Buggy JJ, Elias L. Bruton tyrosine kinase ( Btk) and its role in B -cell malignancy. Int Rev 
Immunol 2012;31:119 -32. Erratum in: Int Rev Immunol 2012;31:428.  
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant 
lymphoma. J Clin Oncol 2007;25:579 -586. 
Cheson BD, Fisher RI, Barrington SF, et al. Recom mendations for initial evaluation, 
staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano 
classification. J Clin Oncol 2014;32:3059 -3067.  
Coiffier B, Lepage E, Briere J, et al.  CHOP chemotherapy plus rituximab compared with 
CHOP alone in elderly patients with diffuse large -B-cell lymphoma.   NEJM 2002;346:[ADDRESS_473350] C HOP 
chemotherapy in DLBCL patients: a study by [CONTACT_79444] d'Etudes des Lymphomes de 
l'Adulte.  Blood 2010;116:2040 -2045.  
de Vos, S, Wilson W, Gerecitano J, et al.  The Bruton  tyrosine kinase ( Btk) inhibitor, 
ibrutinib (PCI -[ZIP_CODE]), has preferential activity  in the activated B cell -like (ABC) subtype of 
relapse/refractory (R/R) DLBCL: interim Phase 2 results.  Haematologica 
2013:98(s1):S1180.  
Dyer M, Hutchinson C, Rule S, et al.  The Bruton’s tyrosine kinase (BTK) inhibitor 
ONO -4059: Single -agent activity in patients with relapsed and refractory non-GCB -DLBCL .  
J Clin Oncol 2014;32(5s):S8553.  
Fisher RI, Gaynor ER, Dahlberg S, et al.  Comparison of a standard regimen (CHOP) with 
three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.   NEJM 
1993;328:1002 -1006.  
Gardner HL, Harrington BK, Izumi R, et al.  ACP-196: A second generation Btk inhibitor 
demonstrates biologic activity in a canine model of B -cell non-Hodgkin lymphoma .  AACR  
[ADDRESS_473351].  
Gisselbrecht C, Glass B, Mou nier N, et al.  Salvage regimens with autologous 
transplantation for relapsed large B -cell lymphoma in the rituximab era.  JCO 
2010;28:4184 -4190.  
Habermann TM, Weller EA, Morrison VA, et al.  Rituximab -CHOP versus CHOP alone or 
with maintenance rituximab i n older patients with diffuse large B -cell lymphoma.  JCO 
2006;24:3121 -3127.  
Honigberg LA, Smith AM, Sirisawad M, et al.  The Bruto n tyrosine kinase inhibitor 
PCI-[ZIP_CODE] blocks B -cell activation and is efficacious in models of autoimmune disease and 
B-cell malignancy. PNAS 2010;107:[ADDRESS_473352], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals. 2014 Dec.  
Available from: http://www.ICMJE.org .  Accessed February 04, 2015.  
International  Non-Hodgkin’s  Lymphoma  Prognostic  Factors  Project A predictive model for 
aggressive non-Hodgkin’s lymphoma. NEJM 1993;329:[ADDRESS_473353]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 70 Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosi ne kinase ( Btk): function, regulation, 
and transformation with special emphasis on the PH domain. Immunol Rev 2009;228:58 -
73. 
Pfreund schuh M, Trümper L, Osterborg A, et al.  CHOP -like chemotherapy plus rituximab 
versus CHOP -like chemotherapy alone in young  patients with good -prognosis diffuse large -
B-cell lymphoma: a randomised controlled trial by [CONTACT_61901] (MInT) 
Group .  Lancet Oncol 2006;7:379 -391. 
Philip T, Gullielmi C, Hagenbeek A, et al.  Autologous bone m arrow transplantation as  
compared with salvage chemotherapy in relapses of chemotherapy -sensitive 
non-Hodgkin's l ymphoma .  NEJM 1995:333:[ADDRESS_473354] survival 
after chemotherapy for diffuse large -B-cell lymphoma.  NEJM 2002;346:1937 -1947.  
Smith, TJ, Khatcheressian J, Lyman GH, et al.  2006 update of recommendations for the 
use of white blood cell growth factors: an evidence based cl inical practice guideline.  J  Clin 
Oncol  2006;24:3187 -3205 . 
Vail DM, Tha mm DH. Spontaneously occurring tumors in companion animals as models for 
drug development. In: Teicher BA, Anders PA, eds. Anticancer Drug Development Guide: 
Preclinical Screening, Clinical Trials, and Approval. 2nd Ed. Totowa, NJ: Human Press; 
2004:259 -284. 
Vail DM, Michels GM, Khanna C, Selting KA, London CA; Veterinary Cooperative Oncology 
Group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) —a 
Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 
2010 ;8:28 -37. 
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase ( Btk) in X -linked 
agammaglobulinemia (XLA). Front Biosci 2000;5:D917 -D928.  
Ziepert M, Hasenclever D, Kuhnt E, et al.  Standard International Prognostic Index remains 
a valid predictor of ou tcome for patients with aggressive CD20+ B-cell lymphoma in the 
rituximab era.  JCO 2010;28:[ADDRESS_473355]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473356]: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 72 Appendix  1.  Performance Status Scores  
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance w ithout 
restriction  
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, eg, light house work, 
office work  
2 Ambulatory and capable of all self -care but unable to carry out any 
work activiti es. Up and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 
50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined 
to bed or chair  
5 Dead  
As published in Am  J Clin Oncol:  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, 
P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin 
Oncol 5:649 -655, 1982.  
Credit: Eastern Cooperative Oncology Group Chair: Robert Comis, MD  
Available at: http://www.ecog.org/general/perf_stat.html .  Accessed August 23, 2013.  
 
 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473357] should be addressed to the medical monitor of this study.  
Strong Inhibitors of CYP3A  Moderate Inhibitors of CYP3A  
boceprevir  aprepi[INVESTIGATOR_378130],b verapamila 
nefazodone   
nelfinavira  
paritaprevir and ritonavir and (ombitasvir 
and/or dasabuvir)b  
posaconazole   
ritonavira, b  
saquinavir and ritonavira, b  
telaprevira  
tipranavir and ritonavira, b  
troleandomycin   
voriconazole   
a. Inhibitor of P -glycoprotein.  
b.  Ritonavir is usually given in combination with other anti -HIV or anti -HCV drugs in 
clinical practice. Caution should be used when extrapolating the observed effect of 
ritonavir alone to the ef fect of combination regimens on CYP3A activities.  
c.  After discontinuation of the strong or moderate CYP3A inhibitor, wait [ADDRESS_473358]. John’s worta  
a. The effect of St. John’s wort varies widely and is preparation -dependent.  
 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 74 P-gp Inhibitors  BCRP Inhibitors  Narrow Therapeutic 
Index P -gp Substrates  
amiodarone  curcumin  digoxin  
carvedilol  cyclosporine A  everolimus  
clarithromycin  eltrombopag  sirolimus  
dronedarone    
itraconazole    
lapatinib    
lopi[INVESTIGATOR_378131] r   
tipranavir and ritonavir    
verapamil    
Source:  FDA Drug Development and Drug Interactions: Table  of Substrates, Inhibitors and 
Inducers. Web link Accessed 18 July 2018: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIn teracti
onsLabeling/ucm093664.htm#inVivo  
 
 
Product: ACP -196 (acalabrutinib)  
Protocol: ACE -LY-[ADDRESS_473359] been caused by [CONTACT_5349]?  
No___ Yes___  
The descriptions provided below wil l help guide the principal investigator [INVESTIGATOR_378132] “yes” or “no”:  
No = There is no reasonable possibility that the event may have been caused by [CONTACT_378159].  
The adverse event:  
 may be judged to be due to extraneous causes such a s disease or environment or 
toxic factors  
 may be judged to be due to the subject’s clinical state or other therapy being 
administered  
 is not biologically plausible  
 does not reappear or worsen when study drug  is re-administered  
 does not follow a temporal se quence from administration of study drug  
Yes = There is a reasonable possibility that the event may have been caused by [CONTACT_378159].  
The adverse event:  
 follows a temporal sequence from administration of study drug  
 is a known response to the study drug based  on clinical or preclinical data  
 could not be explained by [CONTACT_20612]’s clinical state, 
environmental or toxic factors, or other therapy administered to the subject  
 disappears or decreases upon cessation or reduction of dose o f study drug  
 reappears or worsens when study drug is re -administered  
 
 
Product: ACP -196 (acalabrutinib)  
Proto col: ACE -LY-002 
 
 
 
Acerta Pharma   Confidential    Page 76 Appendix  4.  Sche dule of Assessments  
 Screeninga Cycle 1  Cycle 2  Cycle 3  Cycle 4  Cycles 5 -
12b ET/Safety 
Follow Upc LTFUs 
  Days (± 2)  Day(s) (±2)  Day(s) (±2 ) Day(s) (±2)  Day(s) (±2)    
1 2 8  15  22 28  15 28 28 28 28   
Informed consent  x              
Confirm eligibility  x              
Medical history  x              
PEd/Vital signse/Weight x x  x x x x x x x x x x  
ECOG status x x  x x x x x x x x x x  
ECGf x            x  
Lab assessments:               
 Urine pregnancy testg x            x  
 Hematologyh x xt  x x  x x x  x x x x x  
 Serum chemistryi x xt  x x  x x x  x x x x x  
 Urinalysisj x              
 T/B/NK/monocyte  
 cell countk  xv       x   Every 6 
mos   
 Serum Igl  xv       x   Every 6 
mos   
 Bone marrow
 (aspi[INVESTIGATOR_337]/biopsy)m x           For CR 
only   
Hepatitis serologyu x              
HBV PCRv       x  x x x QM  QM 
 Pharmacodynamicsn  x x x   x  x    x  
 Pharmacokineticso  x x x x x x        
 Archival tumor samplep x              
Acalabrutinib  dispensedq  x x x x x x x x x x x   
Study drug compliance  x x x x x x x x x x x   
Tumor assessmentr x        x  x x   
Concomitant medications  x x x x x x x x x x x x x  
Adverse events  x x x x x x x x x x x x x  
Time -to-next treatment               x 
Abbreviations: anti-HBc = hepatitis B core antibody; CR = complete remission; ECG = electrocardiogram ; ECOG = Eastern Cooperative Oncology Group ; ET = early 
termination;  HBsAb = hepatitis B su rface antibody ; HBsAg = hepatitis B surface antigen;  HBV = hepatitis B virus; HCV = hepatitis C virus;  Ig = immunoglobulin; IVIG = 
intravenous immunoglobulins ; LTFU = long -term follow -up; mos = months; PCR = polymerase chain reaction; PE = physical exam; QM = every month.  
Product: ACP-196 (acalabrutinib) 
Protocol: ACE- LY-002 
 
 
 
Acerta Pharma  Confidential   Page 77 Footnotes for ACE- LY-002 Schedule of Study Activities : 
a.  Screening tests should be performed within [ADDRESS_473360] not progressed while receiving study drug treatment, may be eligible to enroll into a long-term follow up study and continue to receive acalabrutinib . 
c. An early termination visit will be done for subjects who permanently discontinue study drug early for any reason. A 30-day (± 7 days) safety follow-up visit is required when 
subjects discontinue study drug unless they start another anticancer therapy within that timeframe. 
d. The screening physical examination will include, at a minimum, the general appearance of the subject, height (screening only) and weight, and examination of the skin, 
eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system.  Symptom-directed physical exams, including 
tumor assessments by [CONTACT_23302], are done thereafter.   
e. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and temperature)  will be assessed after the subject has rested in the sitting position.   
f. Subjects should be in supi[INVESTIGATOR_378124] ≥ [ADDRESS_473361] dose of study drug.  Serum chemistry: albumin, alkaline 
phosphatase, alanine transaminase (ALT) , aspartate aminotransferase ( AST), bicarbonate, blood urea nitrogen (BUN) , calcium, chloride, creatinine , glucose, lactate 
dehydrogenase (LDH), magnesium, phosphate, potassium, sodium, total bilirubin, total protein, and uric acid.  
j. Urinalysis: pH, ketones, specific gravity, bilirubin, protein, blood, and glucose.  
k. T/B/NK cell count (ie, CD3, CD4, CD8 , CD19, CD16/56) .  During Cycle 5-12, only done end of Cycle 6 and 12. 
l.  Serum immunoglobulin: IgG, IgM, IgA .  Du ring Cycle 5-12, only d one end of Cycle [ADDRESS_473362] therapy for 
DLBCL  may use those bone marrow result s in lieu of the baseline bone marrow aspi[INVESTIGATOR_337]/biopsy required for this study provided the biopsy/aspi[INVESTIGATOR_378120] [ADDRESS_473363] dose of study drug .  Thereafter, bone marrow aspi[INVESTIGATOR_378133] . 
n. Pharmacodynamic (PD) assessments will be done on subjects at sites in the [LOCATION_002] . On Cycle 1 Day 1 AND Day 8 the PD samples are drawn predose and 4 hours 
(±10 minutes) postdose.  On Cycle 1 Day 2, Cycle 1 Day 28, and Cycle 2 Day 28, the PD samples are drawn up to 10 minutes predose (ie, the first dose of that day ). At the 
Safety follow-up visit, a PD sample will be collected. Note: Timepoints are relative to the morning dose. 
o. Pharmacokinetic (PK) assessments will be done on subjects at sites in the [LOCATION_002] . PK samples for Cycle 1 Day 1 are drawn predose and at 0.5, 1, 2, 4, 6 and 24 h 
(before first dose on Day 2) postdose. Samples for Cycle [ADDRESS_473364] be drawn 1 hour postdose. Note: Timepoints are relative to the morning dose.  
p. Available archival tumor tissue is required to be eligible for this study.  Either unstained slides (a minimum of 10 slides) or a paraffin block will be acceptable for central 
pathology review. 
q. Acalabrutinib :  For  Cycle 1 Day 1, 2, 8, 15, 22, and 28 study drug (first dose of the day) is administered at the site.    
r. A pretreatment CT scan with contrast (unless contraindicated) is required of the chest, abdomen, and pelvis and any other disease sites (eg, neck) within [ADDRESS_473365] dose of study drug. A pretreatment positron-emission tomography (PET)/CT scan within [ADDRESS_473366] (unless contraindicated) of the chest, abdomen, and pelvis and any other disease sites (eg, 
neck) will be done for tumor assessments at the end of Cycle 2 (± 7 days), Cycle 4 (± 7 days), and Cycle 6 (± 7 days); and then every 3 cycles (12 weeks, ± 7 days) 
thereafter or more frequently at investigator discretion.  At all other visits, tumor assessments will be done by [CONTACT_378149].  Bone marrow and 
PET/CT are only required for confirmation of CR per clinical guidelines (see Section 4.2). At all other visits tumor assessments will be done by [CONTACT_378160]. 
s. Subjects who discontinue study therapy will continue on study for follow-up of safety and time- to-next therapy for DLBCL unless they withdraw consent for further follow- up. 
t. The indicated samples at this timepoint (Cycle 1 Day 1) must be drawn predose. 
u. Hepatitis serology must include hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (anti-HBc), and hepatitis C (HCV) 
antibody.  Subjects who are receiving prophylactic intravenous immunoglobulins (IVIG) and have positive HBsAg or anti-HBc must have negative hepatitis B DNA to be 
eligible.  In addition, any subjects testing positive for any hepatitis serology, must have polymerase chain reaction (PCR) testing (see exclusion criterion #13). 
v. Subjects who are anti-HBc positive (or have a known history of HBV infection) should be monitored monthly with a quantitative PCR test for HBV DNA.   Monthly monitoring 
should continue until [ADDRESS_473367] with a rising viral load (above lower limit of detection) should discontinue acalabrutinib  and 
have antiviral therapy instituted and a consultation with a physician with expertise in managing hepatitis B. 
 
Product: ACP -196 (acalabrutinib)  
Proto col: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 78 Appendix  5.  Actions Required in Cases  of Increases in Liver Biochemistry and Evaluation 
of Hy’s Law  
 
INTRODUCTION  
This Appendix  describes the process to be followed to identify and appropriately report potential 
Hy’s law (PHL) cases and Hy’s law (HL) cases.  It is not intended to be a compreh ensive guide to 
the management of elevated liver biochemistries.  
During the course of the study, the investigator will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for determining whether a subject meets PHL criter ia 
at any point during the study.  All sources of laboratory data are appropriate for the determination 
of PHL and HL events; this includes samples taken at scheduled study visits and other visits, 
including central and all local laboratory evaluations, ev en if collected outside of the study visits 
(e.g.,  PHL criteria could be met by [CONTACT_96724] a central laboratory and/or elevated total 
bilirubin from a local laboratory).  The investigator will also review adverse event (AE) data 
(e.g.,  for AEs th at may indicate elevations in liver biochemistry) for possible PHL events.  
The investigator participates with the sponsor in the review and assessment of cases meeting PHL 
criteria to agree whether HL criteria are met.  HL criteria are met if there is no a lternative 
explanation for the elevations in liver biochemistry other than drug -induced liver injury (DILI) 
caused by [CONTACT_155137] (IMP).  The investigator is responsible for 
recording data pertaining to PHL/HL cases and for report ing AEs and serious adverse events 
(SAEs) according to the outcome of the review and assessment in line with standard 
safety -reporting processes.  
DEFINITIONS  
Potential Hy’s Law  
AST or ALT ≥[ADDRESS_473368] together with total bilirubin ≥[ADDRESS_473369] at any point durin g the study after the 
start of study drug, irrespective of an increase in alkaline phosphatase.  
Hy’s Law  
AST or ALT ≥[ADDRESS_473370] together with total bilirubin ≥[ADDRESS_473371], where no reason other than the IMP 
can be found to explain the combination of increases (e .g., elevated alkaline phosphatase 
indicating cholestasis, viral hepatitis, or another drug).   
For PHL and HL, the elevation in transaminases must precede or be coincident with (i.e.,  on the 
same day) the elevation in total bilirubin, but there is no spec ified timeframe within which the 
elevations in transaminases and total bilirubin must occur.  
Product: ACP -196 (acalabrutinib)  
Proto col: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 79 IDENTIFICATION OF POTENTIAL HY’S LAW CASES  
Laboratory data must be comprehensively reviewed by [CONTACT_378161]:  
 ALT ≥[ADDRESS_473372]  
 AST ≥[ADDRESS_473373]  
 Total  bilirubin ≥[ADDRESS_473374]  
When the identification criteria are met from central or local laboratory results, the investigator will 
perform the following:  
 Notify the sponsor  repres entative/ medical monitor  by [CONTACT_378162]’s law; seriousness criteria “Important medical event” and causality 
assessment “yes/related” or in accordance with the clinical study protocol as appropriate.  
 Request a repeat  of the test (new blo od draw) without delay  
 Complete the appropriate unscheduled laboratory electronic Case Report Form (eCRF) 
module(s)  
 Perform follow -up on subsequent laboratory results according to the guidance provided in the 
clinical study protocol, as applicable  
 
REVIEW  AND ASSESSMENT OF POTENTIAL HY’S LAW CASES  
The instructions in this section should be followed by [CONTACT_378163].  
As soon as possible after the biochemistry abnormality is initially detected, the study medical 
monitor and the investigator will review available data, to agree whether there is an alternative 
explanation for meeting PHL criteria other than DILI caused by [CONTACT_378164] [ADDRESS_473375] and total bilirubin elevations, 
a determination of whether the alternative explanation is an AE will be made and, subsequently, 
whether the AE meets the criteria for an SAE:  
 If the alternative  explanation is not an AE, record the alternative explanation on the 
appropriate eCRF.  
Product: ACP -196 (acalabrutinib)  
Proto col: ACE -LY-002 
 
 
 
Acerta Pharma  Confidential   Page 80  If the alternative explanation is an AE/SAE, update the previously submitted PHL SAE 
accordingly with the new informatio n (reassessing event term, causality, and seriousness 
criteria) following the sponsor’s standard processes.  
If it is agreed that there is  no explanation that would explain the ALT or AST and total bilirubin 
elevations other than the IMP, then:  
 Send updated  SAE (report term “Hy’s law”) according to the sponsor’s standard processes:  
o The “Medically Important” serious criterion should be used if no other serious criteria apply.  
o Because there is no alternative explanation for the HL case, a causality assessment  of 
“related” should be assigned.  
If there is an unavoidable delay of over 15 calendar days in obtaining the information necessary to 
assess whether the case meets the criteria for HL, then it is assumed that there is no alternative 
explanation until an in formed de cision can be made:  
 Provide any further update to the previously submitted SAE  of PHL (report term now “Hy’s law 
case”), ensuring causality assessment is related to IMP and seriousness criteria are medically 
important, according to clinical study protocol process.  
 Continue follow -up and review according to the agreed plan.  After the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are still met.  Update the previously submitted PHL SAE report following 
the clinical study protocol process, according to the outcome of the review.  
ACTIONS REQUIRED FOR REPEAT EPI[INVESTIGATOR_168858]’S LAW  
This section is applicable when a subject meets PHL criteria while receiving study treatment and 
has already met PHL criteria at a previous on -study treatment visit.  The requirement to conduct 
follow -up, review, and assessment of a repeat occurrence(s) of  PHL is based on the nature of the 
alternative cause identified for the previous occurrence.    
 